



HHS Public Access

Author manuscript

Microbiol Spectr. Author manuscript; available in PMC 2019 July 17.

Published in final edited form as:

Microbiol Spectr. 2014 August ; 2(4): MGM2-0014-2013. doi:10.1128/
microbiolspec.MGM2-0014-2013.

Resistance to Isoniazid and Ethionamide in *Mycobacterium tuberculosis*: Genes, Mutations, and Causalities

CATHERINE VILCHÈZE and WILLIAM R. JACOBS JR

Howard Hughes Medical Institute, Department of Microbiology and Immunology, Albert Einstein College of Medicine, Bronx, NY 10461

Abstract

Isoniazid (INH) is the cornerstone of tuberculosis (TB) chemotherapy, used for both treatment and prophylaxis of TB. The antimycobacterial activity of INH was discovered in 1952, and almost as soon as its activity was published, the first INH-resistant *Mycobacterium tuberculosis* strains were reported. INH and its structural analog and second-line anti-TB drug ethionamide (ETH) are pro-drugs. INH is activated by the catalase-peroxidase KatG, while ETH is activated by the monooxygenase EthA. The resulting active species reacts with NAD⁺ to form an INH-NAD or ETH-NAD adduct, which inhibits the enoyl ACP reductase InhA, leading to mycolic acid biosynthesis inhibition and mycobacterial cell death. The major mechanism of INH resistance is mutation in *katG*, encoding the activator of INH. One specific KatG variant, S315T, is found in 94% of INH-resistant clinical isolates. The second mechanism of INH resistance is a mutation in the promoter region of *inhA* (c-15t), which results in *inhA* overexpression and leads to titration of the drug. Mutations in the *inhA* open reading frame and promoter region are also the major mechanism of resistance to ETH, found more often in ETH-resistant clinical isolates than mutations in the activator of ETH. Other mechanisms of resistance to INH and ETH include expression changes of the drugs' activators, redox alteration, drug inactivation, and efflux pump activation. In this article, we describe each known mechanism of resistance to INH and ETH and its importance in *M. tuberculosis* clinical isolates.

THE EMERGENCE OF DRUG RESISTANCE

Tuberculosis (TB) chemotherapy started in the 1930s with the discovery by Domagk and colleagues of the anti-TB activity of sulfonamides. Since these compounds were very toxic and highly insoluble, analogs were synthesized, leading to the discovery of Tibione (thiacetazone, Fig. 1), a highly effective thiosemicarbazone against *Mycobacterium tuberculosis* (1, 2). In parallel, the natural product streptomycin (SM), discovered by Schatz and Waksman, showed activity against *M. tuberculosis* (3) and was used successfully to treat TB patients. Two new anti-TB drugs were discovered soon after: para-aminosalicylic acid (PAS) in 1946 (4) and isonicotinic acid hydrazine (isoniazid, INH) in 1952 (5, 6). Each drug had activity against *M. tuberculosis*; however, drug-resistant mutants emerged rapidly during clinical trials (7–9). To prevent drug resistance, in 1959, SM, PAS, and INH were combined to form the first successful multidrug, biphasic chemotherapy for TB (10). This combination

Correspondence: W. R. Jacobs, Jr., jacobsw@hhmi.org.

treatment was so impressive that Selman Waksman wrote, “the ancient foe of man, known as consumption, the great white plague, tuberculosis, or by whatever other name, is on the way to being reduced to a minor ailment of man. The future appears bright indeed, and the complete eradication of the disease is in sight” (185, p. 217). Nevertheless, the treatment was long and expensive, and patients often dropped out prior to completing chemotherapy. In 1984, a new short-course treatment was established that showed improved efficacy and patient compliance; the drug regimen consisted of two months on INH, rifampicin (RIF), pyrazinamide (PZA), and ethambutol, followed by four months on INH and RIF only.

Despite this successful chemotherapy, the rate of multidrug-resistant (MDR) *M. tuberculosis* strains, defined as strains resistant to INH and RIF, started to increase as early as 1985. Nowadays, the World Health Organization (WHO) estimates that 3.7% of new TB cases and 20% of previously treated TB cases are caused by MDR-TB (11). The highest incidence of MDR-TB (up to 76%) is found in Russia and the former Soviet republics. Extensively drug-resistant (XDR)-TB, defined as TB strains resistant to INH, RIF, fluoroquinolones, and one second-line injectable drug, is found in up to 9% of MDR-TB cases and has been reported in at least 84 countries so far. Furthermore, strains of *M. tuberculosis* that are resistant to up to 10 TB drugs, referred to as totally drug-resistant (TDR-TB), have been isolated in Europe, Africa, India, and Iran (12). One factor in the emergence and rapid spread of drug resistance is the paucity of rapid diagnostics. While new tools are available to quickly assess drug resistance, these methods are based on known drug resistance mechanisms. Understanding all these mechanisms is key to improving diagnosis and eradicating drug-resistant *M. tuberculosis*. In this article, we will discuss the mechanisms that *M. tuberculosis* developed to become resistant to the first-line anti-TB drug INH and its analog, the second-line anti-TB drug ethionamide (ETH).

MODE OF ACTION OF INH AND ETH

INH

The antimycobacterial activity of INH was published and commercialized simultaneously by three independent pharmaceutical companies: Bayer (Neoteben) (13), Hoffman-La Roche (Rimifon) (6), and Squibb Institute for Medical Research (Nydrazid) (5). INH had been first synthesized 40 years earlier and reported in a doctoral thesis; therefore, none of the pharmaceutical companies could patent the discovery. Fox (6) described the discovery of INH as an attempt to combine the anti-TB activity of nicotinamide, which had been found to arrest *M. tuberculosis* growth in guinea pigs (14), and thiosemicarbazones. By replacing the benzene ring of Tibione by the pyridine ring found in nicotinamide (Fig. 1), *meta*- and *para*-pyridylaldehyde thiosemicarbazones were synthesized. All the intermediates in the synthesis of these pyridine thiosemicarbazones were tested for activity against TB, and among them, one intermediate, INH, had antimycobacterial activity far superior to any compound at the time (6). Notably, another analog synthesized, Marsilid (1-isonicotinoyl-2-isopropylhydrazine) (Fig. 1), also showed good anti-TB activity. The use of Marsilid as a TB drug was soon discontinued because it induced euphoria in TB patients. However, Marsilid did go on to become the first antidepressant. Interestingly, the earlier synthetic compounds

active to some degree against *M. tuberculosis* share a similar chemical skeleton (Fig. 1), although their modes of action are different.

The mechanism of action of INH has been the subject of intensive research and controversies since its discovery in 1952. From 1953 to 1980, multiple modes of action for INH were proposed: INH was thought to interfere with cell division (15), pyridoxal-dependent metabolic pathway(s) (16), lipid biosynthesis (17), fatty acid biosynthesis (18), nucleic acid biosynthesis (19), glycerol conversion to hexose phosphate (20), NAD⁺ biosynthesis (21), and NADH dehydrogenase activity (22–23). A major breakthrough in understanding the mechanism of action of INH came with the study by Winder and Collins (186) in which they showed that INH inhibited synthesis of mycolic acids, long-chain α -alkyl β -hydroxy fatty acids that are a crucial component of the mycobacterial cell wall. The effect of INH on mycolic acids has been subsequently confirmed by numerous researchers. Among them, Takayama and coworkers were the first to demonstrate that inhibition of mycolic acid biosynthesis by INH correlated with cell death (24), accumulation of long-chain fatty acids (25), and inhibition of C24 and C26 monounsaturated fatty acid biosyntheses (26). Takayama and colleagues concluded that the mode of action of INH involved a desaturase required for the biosynthesis of these unsaturated fatty acids (26).

INH, like other TB drugs (ETH, PZA, isoxyl, thiacetazone) is a pro-drug. The catalase peroxidase KatG (encoded by *Rv1908c*) activates INH to form a hypothetical isonicotinoyl anion or radical (27–30). This entity reacts with NAD⁺ to yield an INH-NAD adduct, which binds to the active site of the NADH-dependent enoyl-ACP reductase InhA (*Rv1484*) (Fig. 2) (31). This enzyme reduces monounsaturated acyl-ACP to acyl-ACP (32, 33) and is part of the fatty acid synthase type II (FASII) (34). FASII elongates fatty acids up to 56 carbons long where they are derivatized and coupled to a C24-C26 fatty acid generated by FASI to form mycolic acids. The INH-NAD adduct binds to and inhibits InhA (28, 35, 36), leading to disruption of mycolic acid biosynthesis and cell death (37, 38).

ETH

2-Ethylthioisonicotinamide, ETH (Fig. 1), is a structural analog of INH. ETH was first synthesized in 1956 by a French team trying to improve on the antimycobacterial properties of thioisonicotinamide (39). Grumbach and coworkers found that ETH was more active than SM but less so than INH against *M. tuberculosis*. However, ETH was also active against INH-, PAS-, and SM-resistant *M. tuberculosis* strains. ETH was shown to be efficacious in combination with PZA and with or without INH in a clinical trial to treat TB patients infected with INH- and SM-resistant strains (40, 41). Nowadays, ETH is a second-line drug, mostly used to treat MDR-TB cases in South Africa.

Similar to INH (42, 43), *M. tuberculosis* treated with ETH loses its acid fastness (39) and its ability to synthesize mycolic acids (44). ETH is also a pro-drug, activated by the NADPH-specific flavin adenine dinucleotide-containing monooxygenase EthA (also called EtaA, encoded by *Rv3854c*) (45–48). Once activated, the mode of action of ETH is very similar to INH (Fig. 2). The active form of ETH reacts with NAD⁺ to yield an ETH-NAD adduct (49), which inhibits InhA, leading to mycolic acid biosynthesis inhibition. Interestingly, while

KatG only activates INH, EthA activates two other second-line anti-TB drugs: Tibione (thiacetazone) and isoxyl (46, 50).

MECHANISMS OF RESISTANCE TO INH AND ETH

Drug resistance in mycobacteria is due to the acquisition of mutations or efflux pump activation, not due to the acquisition of resistance plasmids or transposons, common resistance mechanisms in other bacterial species. The main mechanisms of resistance to INH and ETH can be divided into two categories. First, prevention of the activation of INH and ETH can be obtained by mutating the activators of the drugs *katG* and *ethA*, respectively, or by mutating regulators of their expression. For example, the *katG*(S315T) mutation is found in up to 94% of INH-resistant *M. tuberculosis* clinical isolates. Second, the inhibition of InhA by the INH-NAD or ETH-NAD adduct can be overcome by mutations in *inhA* or its promoter region. Other mechanisms of resistance exist such as drug inactivators, redox alteration, and efflux pumps. We will first describe the mechanisms of coresistance to INH and ETH and then the mechanisms of resistance specific to each drug.

Common Mechanisms of Resistance to INH and ETH

Clinical isolates coresistant to INH and ETH were isolated from TB patients who had received INH but had never been treated with ETH (51–53). This conundrum led to the hypothesis that INH and ETH shared a common mechanism of resistance, a hypothesis that could not be tested until a plasmid transformation system was developed for mycobacteria (54, 55). It would take another three decades to discover that INH and ETH target the same enzyme in *M. tuberculosis*: the enoyl-ACP reductase InhA (56). Other mechanisms of coresistance to INH and ETH have been discovered. These mechanisms along with resistance mechanisms due to *inhA* mutations are listed below.

Alteration of InhA, the target of INH and ETH—The target of INH and ETH was discovered by isolating a *Mycobacterium smegmatis* mutant coresistant to INH and ETH (56). A genomic DNA cosmid library of this *M. smegmatis* mutant and of drug-susceptible *Myco-bacterium avium*, *Mycobacterium bovis*, *M. smegmatis*, and *M. tuberculosis* strains was constructed and transformed into *M. smegmatis*. A single open reading frame (ORF) was found to be sufficient to confer coresistance to INH and ETH in *M. smegmatis* and was named *inhA*. These experiments demonstrated that a single amino acid mutation in *inhA*(S94A) or overexpression of *inhA* conferred coresistance to INH and ETH in mycobacteria. To prove that *inhA* inactivation was sufficient to lead to death in a manner similar to INH action, a temperature-sensitive mutant in *inhA* was isolated (37). Heat-inactivation of InhA(V238F) mimicked the effects of INH in *M. tuberculosis* described by Takayama and colleagues: inhibition of mycolic acid biosynthesis (24), alteration of the bacterium morphology (57), accumulation of long-chain fatty acids (25), and cell death (24), demonstrating that inhibition of InhA alone reproduced the biochemical characteristics of INH treatment of *M. tuberculosis*. Moreover, the S94A mutation identified in the INH- and ETH-resistant *M. smegmatis* mutant was transferred into wild-type *M. tuberculosis* by specialized linkage transduction, and the resulting strain was at least five times more resistant to INH and ETH than wild-type *M. tuberculosis* (38). This combined set of data

confirms that InhA is the main target and the main mechanism of coresistance to INH and ETH.

The mechanism by which the S94A mutation leads to resistance to INH and ETH has been well studied. InhA is an NADH-dependent enoyl-ACP reductase, and the binding of the enoyl substrate to InhA is not disturbed by the S94A mutation; however, the mutation results in a 5-fold increase in the K_M for the InhA cofactor NADH (32). On the other hand, the ability of the INH-NAD adduct to inhibit InhA(S94A) is markedly reduced, because the IC_{50} and K_i are 17 and 30 times higher, respectively, for the mutated protein. Comparison of the crystal structures of InhA(S94A) to wild-type InhA revealed the loss of a water molecule and disruption of a hydrogen bonding network in the mutated protein, which was enough to reduce the binding of the INH-NAD adduct (38). Others disputed this conclusion and hypothesized that InhA interacts with FASII enzymes and that this interaction is perturbed by the S94A mutation, resulting in INH resistance (58). Overexpression of *inhA* is also a common factor of INH and ETH resistance in clinical isolates. The c-15t base pair change in the *inhA* regulatory region increases *inhA* mRNA levels by 20-fold, resulting in the overexpression of InhA. This leads to a titration of INH or ETH and consequently an eight-fold increase in INH and ETH MICs in *M. tuberculosis* (38).

Numerous point mutations in *inhA* and its promoter region have been identified in INH- and ETH-resistant *M. tuberculosis* clinical isolates (Tables 1 and 2); however, no base pair insertions or deletions have been observed. Mutations in the *inhA* promoter and ORF regions are associated with low-level resistance to INH, even when strains contained mutations in both regions (MIC <1 mg/liter) (59). The c-15t mutation in the promoter region of *inhA* is found in up to 35% of INH-resistant and 55% of ETH-resistant clinical isolates, but never in INH- or ETH-sensitive strains. This mutation was also overly represented in XDR-TB cases in South Africa. In a study on clinical isolates from the Western Cape Province, South Africa, the c-15t mutation was present in 30% of strains mono-resistant to INH, 48% of MDR-TB, and 85% of XDR-TB (60), suggesting that this mutation could be a marker for XDR-TB. Interestingly, in a survey of the Eastern Cape Province clinical isolates, the c-17t *inhA* promoter mutation was the predominant genetic modification present in 83% of XDR-TB cases. The combined *inhA* promoter mutations (at positions -8, -15, and -17) were found in 92% of the XDR-TB cases versus 62% of the MDR-TB cases in the Eastern Cape Province (60).

inhA is an essential gene; therefore, mutations in the coding region of *inhA* are rare. About 15 mutations in *inhA* have been identified in INH-resistant clinical isolates, although two of them were also found in INH-sensitive strains (Table 1). I21T, S94A, and I95P are the only amino acid changes found in both INH- and ETH-resistant clinical isolates. The first mutation identified in *inhA* in *M. smegmatis*, resulting in the S94A variant, has since been found in INH-resistant *M. tuberculosis* clinical isolates with no other mutation present in *katG* or the *fabG-inhA* intergenic region (59, 61). This confirms that the S94A mutation is sufficient to confer INH and ETH resistance in *M. tuberculosis* clinical isolates.

While mutations in the *inhA* promoter region can represent up to 35% of the INH-resistant cases, and mutations in the *inhA* gene are rare in INH-resistant clinical isolates, this is the

predominant region where mutations are found in ETH-resistant clinical isolates. In one study (62), 62% of the ETH-resistant clinical isolates had mutations in *inhA* (gene and/or promoter region), while 47% had mutations in *ethA*. The *inhA* promoter mutation c-15t was therefore proposed as a marker for ETH resistance (63).

Alteration of redox potential—*M. smegmatis* and *M. bovis* BCG mutants coresistant to INH and ETH were isolated in *in vitro* experiments from nonmutagenized independent cultures. The mutants had mutations in *ndh* (*Rv1854c*), a gene encoding a type II NADH dehydrogenase, which oxidizes NADH into NAD⁺. In *M. smegmatis*, the *ndh* mutants contained single base pair changes resulting in amino acid changes and a pleiotropic phenotype: INH resistance, ETH resistance, temperature sensitivity, and for some mutants, Ser/Gly auxotrophy (64, 65). In *M. bovis* BCG, the mutants had either single base pair changes or insertions (65). The *ndh* mutants lost up to 95% of their Ndh activity compared to wild type and had higher levels of NADH, while their NAD⁺ levels were similar to wild type. An increase in NADH concentration was shown to prevent the binding of the INH-NAD adduct to InhA by acting as a competitive inhibitor, leading to INH resistance (65).

In *M. tuberculosis* clinical isolates, *ndh* mutations have been found in both INH-sensitive and INH-resistant strains at a very low rate (66) (Table 1). However, two studies from Singapore and Brazil identified *ndh* mutations in 8 to 10% of INH-resistant *M. tuberculosis* clinical isolates and found no *ndh* mutations in their INH-sensitive clinical isolate strains (67, 68). The R13C mutation was found in a strain containing the *katG* (S315T) mutation, so the contribution to the INH resistance of this *ndh* mutation is uncertain (67). The *ndh* (T110A) mutation was only associated with an *ahpC* mutation resulting in the (T5I) variant (68). However, in that study, *katG* was only partially sequenced, and *inhA* was not (68, 69), so the INH resistance in that isolate may or may not be due to the *ndh*(T110A) mutation. The R268H mutation is the only mutation so far to have been identified in two independent studies and only in INH-resistant strains, but it was associated with *katG*, *inhA*, or *ahpC* mutations (66).

M. tuberculosis has an additional NADH dehydrogenase named *ndhA* (*Rv0392c*). Therefore, mutations in one NADH dehydrogenase such as *ndh* might not alter the redox balance in *M. tuberculosis* and might not lead to INH and/or ETH resistance as long as the second NADH dehydrogenase is functional. *ndh* and *ndhA* are also present in *M. bovis* BCG, but *M. bovis ndhA* codes for a single amino acid change (V241A) relative to *M. tuberculosis*, which might explain why INH- and ETH-resistant *ndh* mutants were isolated in that strain. For that reason, *ndh* mutations might not be a mechanism of resistance to INH and ETH in *M. tuberculosis* unless both NADH dehydrogenase genes are mutated.

Alteration in mycothiol biosynthesis—Mutations in *ndh* in INH-resistant *M. bovis* BCG mutants were isolated *in vitro* by plating nonmutagenized, independent *M. bovis* BCG cultures on plates containing both INH and ETH to avoid mutants carrying mutations in the activator of INH or ETH. When the same experiment was repeated in *M. tuberculosis* H37Rv or the virulent *M. bovis* Ravenel strain, *ndh* mutants were not obtained. Instead, all of the INH- and ETH-resistant *M. tuberculosis* mutants had mutations in *mshA* (*Rv0486*) (70), a gene encoding a glycosyl transferase involved in the biosynthesis of mycothiol (N-

acetylcysteine glucosamine inositol, MSH), while the *M. bovis* mutants coresistant to INH and ETH carried mutations either in *mshA* or in *mshC* (*Rv2130c*) encoding the cysteine ligase of the mycothiol biosynthesis (71). Five enzymes are required to synthesize mycothiol: MshA, MshA2, MshB (Rv1170), MshC, and MshD (Rv0819) (72). Mycothiol is the major thiol and the main reducing and detoxifying agent in mycobacteria (72), yet the role of mycothiol during infection is ambiguous since mycothiol-deficient *M. tuberculosis* strains do not have a growth defect *in vivo* (70). Eight *in vitro* *M. tuberculosis* *mshA* mutants were isolated containing a single base pair modification in *mshA*, resulting in amino acid changes, stop codons, and frameshifts, all of which caused a drastic decrease in mycothiol levels (from 83 to 99.9%). The mutants had different levels of resistance to INH (2-fold to >10-fold) and ETH (4- to 8-fold increase). Complementation with wild-type *M. tuberculosis* *mshA* restored ETH susceptibility but not INH susceptibility in all the mutants. Interestingly, deletion of *mshA* in *M. tuberculosis* led to a strain that did not produce mycothiol and was highly resistant to ETH but fully sensitive to INH (70). This suggests that mycothiol is mostly involved in ETH resistance and might play a role in ETH activation. The observed INH resistance in *M. tuberculosis* *mshA* point mutants and INH susceptibility in *M. tuberculosis* *AmshA* strains might also indicate that *mshA* is required for INH resistance in mycothiol-deficient strains.

In *M. smegmatis*, a 4- to 8-fold increase in INH and ETH resistance was obtained when *mshA* or *mshC* was deleted, while deletion of *mshB* resulted in a strain resistant only to ETH, and deletion of *mshD* had no effect on INH or ETH resistance (73). *M. smegmatis* mycothiol mutants obtained from chemical mutagenesis or transposon insertion had slightly different INH and ETH resistance patterns (74). The role of mycothiol deficiency in INH resistance might be species-dependent. So far, we can only conclude that mutations in *mshA* will result in high-level ETH resistance and at most low-level INH resistance in *M. tuberculosis*.

In a highly INH- and ETH-resistant clinical isolate, a double mutation in *mshA* (V171G, A187V) was found (62). That strain had the *katG*(S315T) mutation to account for the INH resistance but no other mutation to explain its resistance to ETH. However, the *mshA* (A187V) mutation is present in wild-type *M. tuberculosis* Beijing strain. Other *mshA* mutations have also been found in drug-sensitive mycobacterial strains. The N111S mutation is present in *M. tuberculosis* Erdman and Haarlem strains (70, 75), while the *M. bovis* Ravenel and *M. bovis* ATCC19210 strains carry a g316a base pair change in *mshA*, resulting in a G106R amino acid change (71, 75). Mycothiol genes such as *mshA* and *mshC* should be added to the list of candidates responsible for ETH resistance in clinical isolates, although correlation between *mshA* mutations and ETH resistance should be carefully analyzed since mutations in *mshA* might not lead to drug resistance in *M. tuberculosis*.

Degradation of the INH-NAD or ETH-NAD adduct—In a recent study, Wang and colleagues suggested that the NADH pyrophosphatase NudC (Rv3199c), an enzyme from the NAD⁺ recycling pathway, could hydrolyze the INH-NAD or ETH-NAD adduct, leading to INH and ETH resistance (76). *M. smegmatis* and *M. bovis* BCG NudC are functional enzymes, while *M. tuberculosis* H37Rv NudC has a point mutation (Q237P) that renders the enzyme inactive. The authors demonstrated that NudC from *M. smegmatis* and *M. bovis*

BCG could release the adenosine mono-phosphate group from the INH-NAD and ETH-NAD adducts and that overexpression of *M. smegmatis* or *M. bovis* BCG *nudC* resulted in at least a 10-fold increased resistance to INH and ETH, while deletion of *nudC* rendered the strains more sensitive to the drugs. A small portion of *M. tuberculosis* clinical isolates (2%) were found to have the glutamine residue at position 237, suggesting that in these *M. tuberculosis* strains, NudC might be capable of hydrolyzing the adducts. However, no transfer of mutation was performed to prove that this mutation is sufficient to confer INH and ETH resistance in *M. tuberculosis*. The role of *nudC* in INH and/or ETH resistance in *M. tuberculosis* clinical isolates remains to be determined.

Mechanisms of Resistance Specific to INH

Alterations in KatG, the activator of INH—The first mutants isolated in *in vitro* cultures that were highly resistant to INH had the characteristic of being catalase-negative and avirulent in guinea pigs (77, 78). Winder hypothesized that the loss of catalase activity might imply that INH was activated by a catalase to yield some highly reactive species (79). The relationship between INH resistance and the catalase-negative phenotype was elucidated many years later when a highly INH-resistant strain, BHI, a mutant of *M. smegmatis* mc²155 (55), was complemented with an *M. tuberculosis* library (30). INH susceptibility was restored in BHI by the introduction of a single gene, *katG* (*Rv1908c*), encoding a catalase-peroxidase. Furthermore, the authors also found *katG* deletion or mutations in INH-resistant *M. tuberculosis* clinical isolates and demonstrated that transformation of these INH-resistant isolates with a wild-type copy of *katG* restored INH susceptibility (30, 80).

In INH-resistant *M. tuberculosis* clinical isolates, more than 300 mutations in *katG* have been identified throughout the ORF (Table 3). Complete deletion of the gene has been found in clinical isolates, including the first INH-resistant *M. tuberculosis* mutant identified in the Zhang study (30); it has subsequently been identified in other studies (Table 3). Point mutations causing a single amino acid substitution or premature termination, frameshift mutations after addition or deletion of bases, and partial or complete deletion of the gene have been identified. The incidence of *katG* mutations differs between geographical regions but represents at least 30% and up to 95% of INH-resistant clinical isolates.

The most frequent *katG* mutation is at codon S315, where each base (AGC) can be mutated to produce a Thr, Asn, Arg, Ile, Gly, or Leu residue. The S315T mutation can be found in up to 94% of the INH-resistant clinical isolates (81). Two independent biochemical analyses reported that KatG(S315T) has catalase-peroxidase activities, yet its ability to oxidize INH was significantly reduced (82, 83). Biochemical analyses of other KatG mutants showed a wide range of catalase-peroxidase and INH oxidase activities (Table 4). Nevertheless, there is a link between INH oxidase activity and INH resistance. *M. tuberculosis* strains with KatG proteins deficient in INH oxidase activity were highly resistant to INH, while *katG* mutants with INH oxidase activity close to wild-type levels had only 2- to 4-fold increases in the MIC for INH. However, the level of INH resistance might not be defined by location of a mutation: S315T, W341G, G494D, and R595STOP variants are highly resistant to INH (84), while L141F, E553K, and F658V variants are associated with low-level INH resistance (84).

A very common polymorphism, R463L, is often found associated with other *katG* mutations and is more likely to be present in INH-sensitive strains than in INH-resistant strains (85).

The high-level resistance to INH associated with *katG* (S315T) (MIC >1 mg/liter) was reported to be specific to the Ser→Thr amino acid change (59, 86). Brossier and colleagues found *katG*(S315N) only in low-level INH-resistant clinical isolates (62). Curiously, *KatG*(S315N) had been shown to prevent the formation of the INH-NAD adduct, suggesting that INH cannot be activated by *KatG*(S315N), which conflicts with the above mentioned results (87). In a different study, a clinical isolate carrying *katG*(S315N) and *inhA*(c-15t), which is associated with low-level resistance to INH (see above), had an MIC for INH of >256 mg/liter (88). This was the same level of resistance found in clinical isolates where *katG* was missing or the mutation resulted in early termination of the protein (Q434STOP) (88). Furthermore, the INH-resistant clinical isolate containing only the *inhA* promoter mutation had an MIC of 0.19 mg/liter, confirming the low-level INH resistance associated with this mutation. This suggests that *katG*(S315N) might be associated with a high level of INH resistance in clinical isolates.

One of the first studies on the isolation of INH-resistant *M. tuberculosis* mutants *in vitro* found that the mutants could be classified into catalase-negative and highly INH-resistant or catalase-positive and weakly INH-resistant (MIC <10 mg/liter) (89). Catalase-negative mutants were unable to grow in guinea pigs and rabbits, while catalase-positive mutants grew relatively well *in vivo* (90). The relationship between catalase activity and fitness of an INH-resistant strain *in vivo* has been investigated. Pym and colleagues demonstrated that the INH-resistant *M. tuberculosis* *KatG*(T275P) variant had no detectable catalase peroxidase activity and was highly attenuated in a mouse model of infection, while *M. tuberculosis* carrying the *KatG*(S315T) variant was found to be fully virulent in mice, to have no bacterial fitness cost, and to be fully transmissible (91). Consequently, the S315T variant is more often found in MDR-TB patients than in INH mono-resistant clinical isolates (86) and might be related to the higher transmission capabilities of this particular strain (92). A recent study of TB patients showed that those infected with non-*katG* INH-resistant strains (such as *inhA*[c-15t]) were more likely to exhibit sputum conversion after 1 month than those infected with *katG* mutant strains (93). Transmissibility, virulence, and response to chemotherapy seem to be affected by *katG* mutations.

Alterations of *katG* expression—*katG* is cotranscribed with its negative regulator *furA* (*Rv1909c*), a gene encoding a ferric uptake regulation protein (94, 95). Deletion of *furA* in *M. tuberculosis* results in overexpression of *katG* and hypersusceptibility to INH (94). Mutations have been identified in *furA* as well as in the 38-bp region between *furA* and *katG* (Table 1). To assess the role of these mutations, Ando and colleagues constructed isogenic strains containing the mutations found in the intergenic region (g-12a, a-10c, g-7a) or in the *furA* coding sequence (A14V). *katG* expression in the g-12a strain (intergenic region) was only slightly lower than wild-type levels, and the A14V variant had no effect on *KatG* levels (96); however, the strains with the a-10c or g-7a mutation exhibited an 80% reduction in *katG* expression. This reduction was associated with a decrease in INH oxidase activity and a 2- to 4-fold increase in INH resistance, suggesting that the *furA*-*katG* intergenic region should be examined in low-level INH-resistant *M. tuberculosis* clinical strains.

Transcriptional analyses indicate that *katG* is also regulated by the sigma factor *sigI* (*Rv1189*) (97). *M. tuberculosis sigI* had decreased catalase capabilities and was more resistant to INH than wild-type *M. tuberculosis* *in vitro* and *in vivo*. Furthermore, overexpression of *sigI* increased the susceptibility of *M. tuberculosis* to INH by 2-fold. Mutations in *sigI* could therefore be another factor that modulates *katG* expression and induces low-level INH resistance in *M. tuberculosis* clinical isolates.

Compensatory mutations—The activity of INH against mycobacterial species is very specific. Other bacteria such as *Escherichia coli* and *Salmonella typhimurium* are not inhibited by a high dose of INH (500 mg/liter or higher; the MIC for *M. tuberculosis* is 0.05 mg/liter). Yet when *E. coli* and *S. typhimurium* have a deficient oxidative stress response regulator, encoded by *oxyR*, the strains become more sensitive to INH (MIC <50 mg/liter) (98). *M. tuberculosis oxyR*' is nonfunctional, because the coding region contains multiple frameshifts and deletions. Downstream of *oxyR*' is *ahpC* (*Rv2428*), which encodes an alkyl hydroperoxide reductase. Up to 29% of INH-resistant clinical isolates contain mutations in the *oxyR*'-*ahpC* region (99). Mutations in the *oxyR*'-*ahpC* intergenic region such as g-9a and c-15t have been shown to increase the expression of *ahpC* by 9- and 18-fold, respectively (100). This increase in *ahpC* expression is thought to compensate for the loss of KatG activity occurring in INH-resistant strains, which would render the strains more susceptible to hydrogen and organic peroxides (101) and to prevent further oxidative damage. However, most variant KatG enzymes, and in particular, KatG (S315T), are competent catalase-peroxidases, meaning that the organism is not deficient in its ability to detoxify peroxides or other compounds. With the present knowledge, the role of *ahpC* in INH resistance is a matter of debate. Baker et al. reported that mutations in the *oxyR*'-*ahpC* region did not contribute to INH resistance since these mutations could be found in 20% of their INH-resistant clinical isolates but also in 8% of their INH-sensitive isolates (102).

Detoxification of INH—In humans, INH is acetylated by the arylamine *N*-acetyltransferase NAT2. The rate of this detoxification reaction varies between individuals, leading to the classification of TB patients as rapid or slow inactivators depending on their NAT activity. An enzyme similar to NAT is expressed in *M. tuberculosis* (103). When *M. tuberculosis nat* was overexpressed in *M. smegmatis*, the resulting strain was more resistant to INH, with an MIC 3-fold higher than wild-type *M. smegmatis*, suggesting that the mycobacterial arylamine *N*-acetyltransferase can acetylate and inactivate INH (104). Mutations in *nat* (*nhoA/Rv3566c*) have been identified in INH-resistant clinical isolates (Table 1); G67R and G207R variants were found in INH-resistant and INH-sensitive clinical isolates. Biochemical analyses revealed that the K_M for INH *N*-acetylation of Nat (G207R) was 10 times that of wild-type Nat (103), indicating that the variant Nat protein is mostly unable to acetylate and therefore inactivate INH. Thus, there is no obvious association between *nat* mutations and INH resistance. Nevertheless, deletion of *nat* in *M. bovis* BCG affected the biosynthesis of mycolic acids, glycolipids, and complex lipids as well as survival in mouse macrophages, indicating that *nat* might modulate other factors involved in INH resistance (105).

Genes induced upon INH treatment—When *M. tuberculosis* comes in contact with INH, numerous genes are upregulated, as first evidenced using a method that employed differential expression using customized amplification libraries (DECAL) (106). The availability of the *M. tuberculosis* genome sequence (107) led to the development of microarrays that have been used to explore the response of *M. tuberculosis* to INH and other drug treatments (108). Transcriptional analysis of INH-treated *M. tuberculosis* revealed that *M. tuberculosis* upregulated a set of genes encoding proteins involved in fatty acid biosynthesis (*fabD*, *acpM*, *kasA*, *kasB*, *accD6*; *Rv2243–2247*), trehalose dimycolyl transfer (*fbpC*, *Rv0129c*), fatty acid degradation (*fadE23*, *fadE24*; *Rv3139–3140*), peroxidase activity (*ahpC*), transport (*iniB*, *iniA*; *Rv0341–0342*), efflux pump (*efpA*, *Rv2846c*), and unknown functions (*Rv1592c*, *Rv1772*) (106,108). Since genes that respond to drug treatment could be implicated in the mechanisms of resistance to the drug, Ramaswamy and colleagues sequenced all the genes induced by INH except *kasB*, *fadE23*, and *acpM* in 38 INH-resistant and 86 INH-sensitive clinical isolates (88). The *kasA* operon is composed of *fabD*, *acpM*, *kasA*, *kasB*, and *accD6*. *Rv2242*, an *srnR* homolog, is located just upstream of the *kasA* operon and was added to this study. Mutations in *kasA*, *fadE24*, *Rv1592c*, and *Rv2242* were found in INH-resistant strains carrying *katG* mutations or in INH-sensitive strains. No mutations in *fbpC*, *fabD*, *accD6*, or *efpA* were found in INH-resistant clinical isolates. One T4A mutation was found in *Rv1772* in a low-level INH-resistant clinical isolate, with no mutation in the other 19 genes sequenced. This mutation was not found in the INH-sensitive isolates. Another study found a mutation in *efpA* resulting in a variant (E520V) found in INH-resistant strains only but associated with *katG* and *oxyR* ‘-*ahpC* mutations. In conclusion, most of the mutations identified in these genes (except for *Rv1772*) in INH-resistant clinical isolates were found either in INH-sensitive strains or in combination with other mutations known to confer INH resistance. Their roles in INH resistance cannot be assessed at this point.

KasA is a beta-ketoacyl-ACP synthase that condenses an elongating fatty acyl-ACP with malonyl-ACP and is the first enzyme in the FASII system. KasA was once considered a more likely target of INH than InhA based on the fact that INH treatment of *M. tuberculosis* resulted in the inhibition of mycolic acid biosynthesis and accumulation of the long-chain fatty acid hexacosanoic acid. The accumulation of fatty acids correlated better with the inhibition of a beta-ketoacyl-ACP synthase (KasA) than with the inhibition of an enoyl-ACP reductase (InhA), which should result in the accumulation of enoyl products (unsaturated fatty acids) (109). This biochemical red herring, however, did not consider the work of Takayama and coworkers, who demonstrated that a short exposure (5 min) of *M. tuberculosis* to INH resulted in the accumulation of unsaturated fatty acids, while longer INH exposures led to accumulation of hexacosanoic acid due to the total shutdown of the FASII system (26). Mdluli et al. demonstrated that in INH-treated *M. tuberculosis*, KasA formed a complex with INH and the acyl carrier protein AcpM and identified four variants in KasA (D66N, G269S, G312S, F413L) in INH-resistant clinical isolates (109). The authors thus concluded that KasA was the main target of INH. This conclusion was disproved by the demonstration that the complex between KasA, INH, and AcpM was formed only when InhA was inhibited (110) and by the discovery of the KasA variants D66N, G269S, and G312S in INH-sensitive strains (66). Other *kasA* mutations have been

identified in INH-resistant *M. tuberculosis* clinical isolates; however, these mutations are usually associated with *katG* mutations.

The INH-inducible gene *iniA* was shown to confer tolerance to INH when overexpressed in *M. bovis* BCG but not in *M. tuberculosis*, while deletion of *iniA* rendered *M. tuberculosis* more susceptible to INH (111). *iniA* is in an operon with the INH-inducible genes *iniB* and *iniC*. Immediately upstream of this operon is *Rv0340*, which is transcribed in the same direction. This operon is induced specifically by drugs inhibiting mycobacterial cell wall biosynthesis such as INH and ethambutol (112). The *iniBAC* operon encodes a membrane transporter, but it was shown not to transport INH (111). All the mutations in this cluster (Table 1) were only present in INH-resistant clinical isolates; however, they were always associated with mutations in *katG* and/or *inhA*. Hence, mutations in the *iniBAC* operon may only have a minor role in INH resistance.

Interestingly, the target of INH and ETH, *inhA*, is not upregulated upon INH or ETH treatment of *M. tuberculosis*, which may be an important determinant of successful drug targets.

Overexpression of NAD⁺/NADP⁺-binding enzymes—The INH-sensitive *E. coli* *oxyR* mutant described above was also used to identify other molecular determinants of INH resistance in *M. tuberculosis*. The *E. coli* mutant was transformed with an *M. tuberculosis* genomic plasmid library and screened for clones that became INH-resistant. Three genes, *glf* (*ceoA*), *ceoB*, and *ceoC*, restored INH resistance in *E. coli*. Each gene contains an NAD⁺ binding motif. Only overexpression of *M. tuberculosis glf* (*Rv3809c*), an NAD⁺- and flavin adenine dinucleotide-dependent UDP galactopyranose mutase, led to low-level INH resistance in BCG. However, a binding experiment with radioactive INH showed that Glf did not bind to INH. The authors concluded that upregulation of NAD⁺-binding proteins might play a role in INH resistance by either reducing the levels of NAD⁺ available for the formation of the INH-NAD adduct or by binding an unknown derivative of INH (113).

The finding that the NADPH-dependent β -ketoacyl-ACP reductase FabG (*Rv1483*), part of the FASII system, was inhibited *in vitro* by an INH-NADP adduct similarly to *InhA* (114) led others to investigate whether additional enzymes could be inhibited by this INH-NADP adduct. The enzymatic activity of the *M. tuberculosis* dihydrofolate reductase DHFR (*Rv2763c*), the target of the broad-spectrum antibiotic trimethoprim, was shown to be inhibited by the 4*R*-INH-NADP adduct with subnanomolar affinity (115). Overexpression of *M. tuberculosis dfrA* in *M. smegmatis* increased INH resistance by 2-fold at 30°C (115). However, overexpression of *M. tuberculosis dfrA* in *M. tuberculosis* did not increase resistance to INH (116), and the sequences of 127 INH-resistant clinical isolates revealed no mutation in *dfrA*, suggesting that DHFR is not a marker for INH resistance in *M. tuberculosis* (117). Affinity chromatography identified 16 other proteins that could bind to the INH-NAD or INH-NADP adduct (118), but overexpression of the *M. tuberculosis* genes encoding these proteins did not confer resistance to INH or ETH in *M. smegmatis* (116).

Overexpression of efflux pumps—Active export of drugs from cells by efflux pumps was first described in *E. coli* for tetracycline (119). In mycobacteria, low-level resistance to

tetracycline and other aminoglycosides has been attributed to efflux pumps (120, 121). *iniA*, a gene induced by INH treatment (106), was shown to be a component of an MDR-like efflux pump. Overexpression of *iniA* conferred tolerance to INH, while deletion of *iniA* increased the susceptibility of mycobacteria to INH (111). However, IniA does not pump INH out of the cells.

A microarray study of *M. tuberculosis* clinical isolates resistant to INH, RIF, SM, ethambutol, and ofloxacin revealed that upon INH treatment, expression of several predicted efflux pump genes was upregulated: *Rv1819c*, *Rv2459*, *Rv2846*, *Rv3065*, and *Rv3728* (122). Furthermore, administration of an efflux pump inhibitor decreased the MIC for INH in these strains by at least 4-fold, suggesting that these efflux pumps may play a role in drug resistance in *M. tuberculosis*.

Rv1217c-1218c, an operon encoding an ATP binding cassette transporter, was shown by RT-qPCR to be overexpressed in MDR- and XDR-TB strains; the overexpression of *Rv1218C* was associated with increased INH resistance (123). However, deletion of *Rv1218c* did not affect the MIC of INH in *M. tuberculosis* (124), nor did deletion of other efflux pumps such as *Rv1877*, *mmr*, and *mmpL7* (125,126), although overexpression of *mmpL7* conferred resistance to INH (127). Conversely, deletion of *lfrA* led to a 2-fold decrease in the INH MIC (126). Unexpectedly, deletion of *efpA*, which encodes an efflux pump that is specifically induced upon INH treatment of *M. tuberculosis*, resulted in increased resistance to INH and RIF in *M. smegmatis* (126).

In light of these studies, the role of efflux pumps in INH resistance in *M. tuberculosis* needs to be further evaluated in order to assess their importance in the resistance mechanisms.

Mechanisms of Resistance to ETH Only

Alterations of EthA, the activator of ETH—The mechanisms of resistance to ETH are mutations in genes encoding its activator (*ethA*), its target (*inhA*), or the *ethA* regulator (*ethR*). So far, 85 *ethA* mutations have been identified, although some were also found in drug-susceptible or partially ETH-resistant *M. tuberculosis* strains (Table 2). Mutations have been identified throughout the length of the coding region. Approximately two-thirds of the nucleotide changes are missense mutations that result in amino acid changes, while the remaining mutations are insertions, deletions, or nonsense mutations. Unlike the *katG*(S315T) variant, which can be present in up to 94% of the INH-resistant clinical isolates, no dominant *ethA* mutation occurs in ETH-resistant clinical isolates. Morlock and colleagues (61) hypothesized that the lack of cluster or dominant *ethA* mutations in ETH-resistant clinical isolates could be attributed to the presence of numerous monooxygenase homologs in *M. tuberculosis* that could protect the cells against a loss of EthA activity.

In a study by Brossier and colleagues (62), 47 ETH-resistant clinical isolates were analyzed for mutations in *ethA*, *ethR*, *inhA*, *ndh*, or *mshA*. Of these, 22 clinical isolates (47%) had mutations in *ethA*, while 29 strains (62%) had a mutation in *inhA* (promoter region/gene). On average, the proportion of *inhA* mutations in ETH-resistant clinical isolates is 68%, suggesting that this is the main mechanism of ETH resistance in *M. tuberculosis*.

Mutations in *ethR*, the regulator of *ethA*—*ethA* is negatively regulated by EthR (Rv3855), a transcriptional repressor belonging to the TetR family. The two genes are oriented opposite to each other, separated by a 73-bp intergenic region that contains the *ethA* promoter and to which EthR binds. A strain with a transposon insertion in *ethR* was highly sensitive to ETH, while *ethR* overexpression increased the resistance to ETH (45). Two mutations in *ethR* have been identified (Table 2) in highly ETH-resistant clinical strains, which represent 4% of ETH-resistant clinical strains screened; however, these two strains also contained the c-15t mutation in the promoter region of *inhA*, and one of the two had a mutation in *ethA* as well (62). Since the majority of ETH-resistant clinical isolates have mutations in *ethA* and/or *inhA*, *ethR* might only play a minor role in ETH resistance in *M. tuberculosis* clinical isolates.

CONCLUSIONS AND THE FUTURE

The mechanisms of resistance to INH and ETH in *M. tuberculosis* are both simple and complex (Fig. 3). The main mechanisms of resistance are mutations in *katG* and *ethA*, the activators of INH and ETH, respectively, preventing the formation of the INH-NAD or ETH-NAD adduct, and mutations in *inhA*, the target of INH and ETH, leading to titration of the drug or reduced binding of the INH-NAD or ETH-NAD adduct to InhA. Numerous mutations in multiple genes have been identified in INH- or ETH-resistant *M. tuberculosis* clinical isolates (Tables 1 to 3). Ultimately, the validation of a mutation responsible for INH or ETH resistance requires transferring the point mutation into wild-type *M. tuberculosis* and measuring the level of resistance. This is far beyond the scope of most studies that describe mutations associated with drug resistance in *M. tuberculosis*.

It is often reported that a certain percentage (up to 30%) of INH-resistant *M. tuberculosis* clinical isolates have no mutation in any of the genes studied, leading some to conclude that there is still much more to discover about INH and ETH mode of action and resistance. Yet most studies sequenced only a small fraction of the genes known to confer INH resistance such as *katG* and *inhA*, looking only at the region around codon 315 of *katG* or the regulatory region of *inhA*. However, more than 300 mutations have been identified in *katG* from amino acids 1 to 735 (Table 3), and mutations outside of the S315 region have also been shown to be highly defective in INH activation. Sequencing only a fraction of the *katG* gene around the S315 region might leave mutations responsible for the drug resistance phenotype undiscovered. Nevertheless, in studies where the *katG* and *inhA* genes and their regulatory regions are entirely sequenced, the mechanism of resistance is not identified in up to 5% of the INH-resistant clinical isolates.

Additional mechanisms of resistance likely remain to be identified, and a worthwhile endeavor may be to revisit the early studies on INH mechanisms of action to determine other factors of INH and ETH resistance in *M. tuberculosis*. Knowledge of resistance genes and mutations has provided the means to develop GenoType MTBDR_{plus}, a rapid nucleic acid-based test for assessing INH and RIF resistance (128). Moreover, it may provide strategies to develop new drugs that bypass the known mechanisms of drug resistance. For example, the natural product pyridomycin inhibits InhA without requiring KatG activation and is therefore active against highly INH-resistant *M. tuberculosis* clinical isolates carrying a *katG*

mutation (129). The identification of additional genes contributing to INH and ETH resistance will also expand our understanding of the mechanisms of drug action. Finally, in addition to specific mutations that confer resistance to every cell in a population, new studies that reveal the way in which a cell can become transiently phenotypically resistant to INH or ETH will be important in developing better ways to kill *M. tuberculosis* with INH and ETH and shorten chemotherapy.

REFERENCES

1. Behnisch R, Mietzsch F, Schmidt H. 1950 Chemical studies on thiosemicarbazones with particular reference to antituberculous activity. *Am Rev Tuberc* 61:1–7. [PubMed: 15398011]
2. Domagk G 1950 Investigations on the antituberculous activity of the thiosemicarbazones in vitro and in vivo. *Am Rev Tuberc* 61:8–19. [PubMed: 15398012]
3. Schatz A, Waksman SA. 1944 Effect of streptomycin upon *Mycobacterium tuberculosis* and related organisms. *Proc Soc Exp Biol Med* 57:244–248.
4. Lehmann J 1946 para-Aminosalicylic acid in the treatment of tuber-culosis. *Lancet* 247:15.
5. Bernstein JW, Lott A, Steinberg BA, Yale HL. 1952 Chemotherapy of experimental tuberculosis. *Am Rev Tuberc* 65:357–374. [PubMed: 14903503]
6. Fox HH. 1952 The chemical approach to the control of tuberculosis. *Science* 116:129–134. [PubMed: 14950210]
7. Medical Research Council Investigation. 1950 Treatment of pulmonary tuberculosis with streptomycin and para-amino-salicylic acid. *Br Med J* 2:1073–1085. [PubMed: 14772553]
8. Medical Research Council Investigation. 1952 The treatment of pulmonary tuberculosis with isoniazid. *Br Med J* 2:735–746. [PubMed: 12978309]
9. Crofton J, Mitchison DA. 1948 Streptomycin resistance in pulmonary tuberculosis. *Br Med J* 2:1009–1015. [PubMed: 18100441]
10. Crofton J 1959 Chemotherapy of pulmonary tuberculosis. *Br Med J* 1:1610–1614. [PubMed: 13662631]
11. WHO. 2012. Global Tuberculosis Report 2012. Geneva, Switzerland.
12. Cegielski P, Nunn P, Kurbatova EV, Weyer K, Dalton TL, Wares DF, Iademarco MF, Castro KG, Raviglione M. 2012 Challenges and controversies in defining totally drug-resistant tuberculosis. *Emerg Infect Dis* 18:e2.
13. Domagk G, Offe HA, Siefken W. 1952 [Additional investigations in experimental chemotherapy of tuberculosis (neotaban)]. *Dtsch Med Wochenschr* 77:573–578. [PubMed: 14954737]
14. Chorine V 1945 Action of nicotinamide on bacilli of the species *Mycobacterium*. *Compt Ren* 220:150–151.
15. Barclay WR, Ebert RH, Kochweser D. 1953 Mode of action of isoniazid. *Am Rev Tuberc* 67:490–496. [PubMed: 13031065]
16. Pope H 1953 Antagonism of isoniazid by certain metabolites. *Am Rev Tuberc* 68:938–939. [PubMed: 13104908]
17. Russe HP, Barclay WR. 1955 The effect of isoniazid on lipids of the tubercle bacillus. *Am Rev Tuberc* 72:713–717. [PubMed: 13268845]
18. Ebina T, Motomiya M, Munakata K, Kobuya G. 1961 Effect of isoniazid on fatty acids in *Mycobacterium*. *CR Seances Soc Biol Fil* 155:1176–1178.
19. Gangadharam PRJ, Harold FM, Schaefer W. 1963 Selective inhibition of nucleic acid synthesis in *Mycobacterium tuberculosis* by isoniazid. *Nature* 198:712–714.
20. Winder FG, Brennan P. 1965 Effect of isoniazid on lipid metabolism in *Mycobacterium tuberculosis*. *Biochem J* 96:77P.
21. Bekierkunst A 1966 Nicotinamide-adenine dinucleotide in tubercle bacilli exposed to isoniazid. *Science* 152:525–526. [PubMed: 4286359]

22. Davis WE, Weber MM. 1977 Specificity of isoniazid on growth inhibition and competition for an oxidized nicotinamide adenine dinucleotide regulatory site on the electron transport pathway in *Mycobacterium phlei*. *Antimicrob Agents Chemother* 12:213–218. [PubMed: 197885]
23. Herman RP, Weber MM. 1980 Site of action of isoniazid on the electron transport chain and its relationship to nicotinamide adenine dinucleotide regulation in *Mycobacterium phlei*. *Antimicrob Agents Chemother* 17:450–454. [PubMed: 7425605]
24. Takayama K, Wang L, David HL. 1972 Effect of isoniazid on the in vivo mycolic acid synthesis, cell growth, and viability of *Mycobacterium tuberculosis*. *Antimicrob Agents Chemother* 2:29–35. [PubMed: 4208567]
25. Takayama K, Schnoes HK, Armstrong EL, Boyle RW. 1975 Site of inhibitory action of isoniazid in the synthesis of mycolic acids in *Mycobacterium tuberculosis*. *J Lipid Res* 16:308–317. [PubMed: 806645]
26. Davidson LA, Takayama K. 1979 Isoniazid inhibition of the synthesis of monounsaturated long-chain fatty acids in *Mycobacterium tuberculosis* H37Ra. *Antimicrob Agents Chemother* 16:104–105. [PubMed: 112917]
27. Johnsson K, Schultz PG. 1994 Mechanistic studies of the oxidation of isoniazid by the catalase peroxidase from *Mycobacterium tuberculosis*. *J Am Chem Soc* 116:7425–7426.
28. Lei B, Wei CJ, Tu SC. 2000 Action mechanism of antitubercular isoniazid. Activation by *Mycobacterium tuberculosis* KatG, isolation, and characterization of inhA inhibitor. *J Biol Chem* 275:2520–2526. [PubMed: 10644708]
29. Wilming M, Johnsson K. 1999 Spontaneous formation of the bio-active form of the tuberculosis drug isoniazid. *Angew Chem Int Ed Engl* 38:2588–2590. [PubMed: 10508348]
30. Zhang Y, Heym B, Allen B, Young D, Cole S. 1992 The catalase-peroxidase gene and isoniazid resistance of *Mycobacterium tuberculosis*. *Nature* 358:591–593. [PubMed: 1501713]
31. Rozwarski DA, Grant GA, Barton DH, Jacobs WR Jr, Sacchettini JC. 1998 Modification of the NADH of the isoniazid target (InhA) from *Mycobacterium tuberculosis*. *Science* 279:98–102. [PubMed: 9417034]
32. Dessen A, Quemard A, Blanchard JS, Jacobs WR Jr, Sacchettini JC. 1995 Crystal structure and function of the isoniazid target of *Mycobacterium tuberculosis*. *Science* 267:1638–1641. [PubMed: 7886450]
33. Quemard A, Sacchettini JC, Dessen A, Vilcheze C, Bittman R, Jacobs WR Jr, Blanchard JS. 1995 Enzymatic characterization of the target for isoniazid in *Mycobacterium tuberculosis*. *Biochemistry* 34:8235–8241. [PubMed: 7599116]
34. Marrakchi H, Laneelle G, Quemard A. 2000 InhA, a target of the antituberculous drug isoniazid, is involved in a mycobacterial fatty acid elongation system, FAS-II. *Microbiology* 146(Pt 2):289–296. [PubMed: 10708367]
35. Nguyen M, Quemard A, Broussy S, Bernadou J, Meunier B. 2002 Mn(III) pyrophosphate as an efficient tool for studying the mode of action of isoniazid on the InhA protein of *Mycobacterium tuberculosis*. *Antimicrob Agents Chemother* 46:2137–2144. [PubMed: 12069966]
36. Rawat R, Whitty A, Tonge PJ. 2003 The isoniazid-NAD adduct is a slow, tight-binding inhibitor of InhA, the *Mycobacterium tuberculosis* enoyl reductase: adduct affinity and drug resistance. *Proc Natl Acad Sci USA* 100:13881–13886. [PubMed: 14623976]
37. Vilcheze C, Morbidoni HR, Weisbrod TR, Iwamoto H, Kuo M, Sacchettini JC, Jacobs WR Jr. 2000 Inactivation of the inhA-encoded fatty acid synthase II (FASII) enoyl-acyl carrier protein reductase induces accumulation of the FASI end products and cell lysis of *Mycobacterium smegmatis*. *J Bacteriol* 182:4059–4067. [PubMed: 10869086]
38. Vilcheze C, Wang F, Arai M, Hazbon MH, Colangeli R, Kremer L, Weisbrod TR, Alland D, Sacchettini JC, Jacobs WR Jr. 2006 Transfer of a point mutation in *Mycobacterium tuberculosis* inhA resolves the target of isoniazid. *Nat Med* 12:1027–1029. [PubMed: 16906155]
39. Grumbach F, Rist N, Libermann D, Moyeux M, Cals S, Clavel S. 1956 Experimental antituberculous activity of certain isonicotinic thioamides substituted on the nucleus. *CR Hebd Seances Acad Sci* 242:2187–2189. (In French.)

40. Brouet G, Marche J, Rist N, Chevallier J, Lemeur G. 1959 Observations on the antituberculous effectiveness of alpha-ethyl-thioisonicotinamide in tuberculosis in humans. *Am Rev Tuberc* 79:6–18. [PubMed: 13606330]
41. Petty TL, Mitchell RS. 1962 Successful treatment of advanced isoniazid- and streptomycin-resistant pulmonary tuberculosis with ethionamide, pyrazinamide, and isoniazid. *Am Rev Respir Dis* 86:503–512. [PubMed: 13942996]
42. Middlebrook G. 1952 Sterilization of tubercle bacilli by isonicotinic acid hydrazide and the incidence of variants resistant to the drug in vitro. *Am Rev Tuberc* 65:765–767. [PubMed: 14924201]
43. Schaefer WB. 1954 The effect of isoniazid on growing and resting tubercle bacilli. *Am Rev Tuberc* 69:125–127. [PubMed: 13114634]
44. Winder FG, Collins PB, Whelan D. 1971 Effects of ethionamide and isoxyl on mycolic acid synthesis in *Mycobacterium tuberculosis* BCG. *J Gen Microbiol* 66:379–380. [PubMed: 4999216]
45. Baulard AR, Betts JC, Engohang-Ndong J, Quan S, McAdam RA, Brennan PJ, Loch C, Besra GS. 2000 Activation of the pro-drug ethionamide is regulated in mycobacteria. *J Biol Chem* 275:28326–28331. [PubMed: 10869356]
46. DeBarber AE, Mdluli K, Bosman M, Bekker LG, Barry CE 3rd. 2000 Ethionamide activation and sensitivity in multidrug-resistant *Mycobacterium tuberculosis*. *Proc Natl Acad Sci USA* 97:9677–9682. [PubMed: 10944230]
47. Fraaije MW, Kamerbeek NM, Heidekamp AJ, Fortin R, Janssen DB. 2004 The prodrug activator EtaA from *Mycobacterium tuberculosis* is a Baeyer-Villiger monooxygenase. *J Biol Chem* 279:3354–3360. [PubMed: 14610090]
48. Vannelli TA, Dykman A, Ortiz de Montellano PR. 2002 The anti-tuberculosis drug ethionamide is activated by a flavoprotein mono-oxygenase. *J Biol Chem* 277:12824–12829. [PubMed: 11823459]
49. Wang F, Langley R, Gulten G, Dover LG, Besra GS, Jacobs WR Jr, Sacchettini JC. 2007 Mechanism of thioamide drug action against tuberculosis and leprosy. *J Exp Med* 204:73–78. [PubMed: 17227913]
50. Dover LG, Alahari A, Gratraud P, Gomes JM, Bhowruth V, Reynolds RC, Besra GS, Kremer L. 2007 EthA, a common activator of thiocarbamide-containing drugs acting on different mycobacterial targets. *Antimicrob Agents Chemother* 51:1055–1063. [PubMed: 17220416]
51. Hok TT. 1964 A comparative study of the susceptibility to ethionamide, thiosemicarbazone, and isoniazid of tubercle bacilli from patients never treated with ethionamide or thiosemicarbazone. *Am Rev Respir Dis* 90:468–469. [PubMed: 14215919]
52. Stewart SM, Hall E, Riddell RW, Somner AR. 1962 Bacteriological aspects of the use of ethionamide, pyrazinamide and cycloserine in the treatment of chronic pulmonary tuberculosis. *Tubercle* 43:417–431. [PubMed: 13993194]
53. Lefford MJ. 1966 The ethionamide sensitivity of British pre-treatment strains of *Mycobacterium tuberculosis*. *Tubercle* 47:198–206. [PubMed: 4960414]
54. Snapper SB, Lugosi L, Jekkel A, Melton RE, Kieser T, Bloom BR, Jacobs WR Jr. 1988 Lysogeny and transformation in mycobacteria: stable expression of foreign genes. *Proc Natl Acad Sci USA* 85:6987–6991. [PubMed: 2842799]
55. Snapper SB, Melton RE, Mustafa S, Kieser T, Jacobs WR Jr. 1990 Isolation and characterization of efficient plasmid transformation mutants of *Mycobacterium smegmatis*. *Mol Microbiol* 4:1911–1919. [PubMed: 2082148]
56. Banerjee A, Dubnau E, Quemard A, Balasubramanian V, Um KS, Wilson T, Collins D, de Lisle G, Jacobs WR Jr. 1994 inhA, a gene encoding a target for isoniazid and ethionamide in *Mycobacterium tuberculosis*. *Science* 263:227–230. [PubMed: 8284673]
57. Takayama K, Wang L, Merkal RS. 1973 Scanning electron microscopy of the H37Ra strain of *Mycobacterium tuberculosis* exposed to isoniazid. *Antimicrob Agents Chemother* 4:62–65. [PubMed: 4208900]
58. Dias MV, Vasconcelos IB, Prado AM, Fadel V, Basso LA, de Azevedo WF Jr Santos DS. 2007 Crystallographic studies on the binding of isonicotinyl-NAD adduct to wild-type and isoniazid

- resistant 2-trans-enoyl-ACP (CoA) reductase from *Mycobacterium tuberculosis*. *J Struct Biol* 159:369–380. [PubMed: 17588773]
59. Brossier F, Veziris N, Truffot-Pernot C, Jarlier V, Sougakoff W. 2006 Performance of the genotype MTBDR line probe assay for detection of resistance to rifampin and isoniazid in strains of *Mycobacterium tuberculosis* with low- and high-level resistance. *J Clin Microbiol* 44:3659–3664. [PubMed: 17021094]
 60. Muller B, Streicher EM, Hoek KG, Tait M, Trollip A, Bosman ME, Coetzee GJ, Chabula-Nxiweni EM, Hoosain E, Gey van Pittius NC, Victor TC, van Helden PD, Warren RM. 2011 *inhA* promoter mutations: a gateway to extensively drug-resistant tuberculosis in South Africa? *Int J Tuberc Lung Dis* 15:344–351. [PubMed: 21333101]
 61. Morlock GP, Metchock B, Sikes D, Crawford JT, Cooksey RC. 2003 *ethA*, *inhA*, and *katG* loci of ethionamide-resistant clinical *Mycobacterium tuberculosis* isolates. *Antimicrob Agents Chemother* 47:3799–3805. [PubMed: 14638486]
 62. Brossier F, Veziris N, Truffot-Pernot C, Jarlier V, Sougakoff W. 2011 Molecular investigation of resistance to the antituberculous drug ethionamide in multidrug-resistant clinical isolates of *Mycobacterium tuberculosis*. *Antimicrob Agents Chemother* 55:355–360. [PubMed: 20974869]
 63. Vadwai V, Ajbani K, Jose M, Vineeth VP, Nikam C, Deshmukh M, Shetty A, Soman R, Rodrigues C. 2012 Can *inhA* mutation predict ethionamide resistance? *Int J Tuberc Lung Dis* 17:129–130. [PubMed: 23146620]
 64. Miesel L, Weisbrod TR, Marcinkeviciene JA, Bittman R, Jacobs WR Jr. 1998 NADH dehydrogenase defects confer isoniazid resistance and conditional lethality in *Mycobacterium smegmatis*. *J Bacteriol* 180:2459–2467. [PubMed: 9573199]
 65. Vilcheze C, Weisbrod TR, Chen B, Kremer L, Hazbon MH, Wang F, Alland D, Sacchettini JC, Jacobs WR Jr. 2005 Altered NADH/NAD⁺ ratio mediates coresistance to isoniazid and ethionamide in mycobacteria. *Antimicrob Agents Chemother* 49:708–720. [PubMed: 15673755]
 66. Hazbon MH, Brimacombe M, Bobadilla del Valle M, Cavatore M, Guerrero MI, Varma-Basil M, Billman-Jacobe H, Lavender C, Fyfe J, Garcia-Garcia L, Leon CI, Bose M, Chaves F, Murray M, Eisenach KD, Sifuentes-Osornio J, Cave MD, Ponce de Leon A, Alland D. 2006 Population genetics study of isoniazid resistance mutations and evolution of multidrug-resistant *Mycobacterium tuberculosis*. *Antimicrob Agents Chemother* 50:2640–2649. [PubMed: 16870753]
 67. Cardoso RF, Cardoso MA, Leite CQ, Sato DN, Mamizuka EM, Hirata RD, de Mello FF, Hirata MH. 2007 Characterization of *ndh* gene of isoniazid resistant and susceptible *Mycobacterium tuberculosis* isolates from Brazil. *Mem Inst Oswaldo Cruz* 102:59–61. [PubMed: 17294000]
 68. Lee AS, Teo AS, Wong SY. 2001 Novel mutations in *ndh* in isoniazid-resistant *Mycobacterium tuberculosis* isolates. *Antimicrob Agents Chemother* 45:2157–2159. [PubMed: 11408244]
 69. Lee AS, Lim IH, Tang LL, Telenti A, Wong SY. 1999 Contribution of *kasA* analysis to detection of isoniazid-resistant *Mycobacterium tuberculosis* in Singapore. *Antimicrob Agents Chemother* 43:2087–2089. [PubMed: 10428945]
 70. Vilcheze C, Av-Gay Y, Attarian R, Liu Z, Hazbon MH, Colangeli R, Chen B, Liu W, Alland D, Sacchettini JC, Jacobs WR Jr. 2008 Mycothiol biosynthesis is essential for ethionamide susceptibility in *Mycobacterium tuberculosis*. *Mol Microbiol* 69:1316–1329. [PubMed: 18651841]
 71. Vilcheze C, Av-Gay Y, Barnes SW, Larsen MH, Walker JR, Glynn RJ, Jacobs WR Jr. 2011 Coresistance to isoniazid and ethionamide maps to mycothiol biosynthetic genes in *Mycobacterium bovis*. *Antimicrob Agents Chemother* 55:4422–4423. [PubMed: 21709101]
 72. Newton GL, Buchmeier N, Fahey RC. 2008 Biosynthesis and functions of mycothiol, the unique protective thiol of Actinobacteria. *Microbiol Mol Biol Rev* 72:471–494. [PubMed: 18772286]
 73. Xu X, Vilcheze C, Av-Gay Y, Gomez-Velasco A, Jacobs WR Jr. 2011 Precise null deletion mutations of the mycothiol synthesis genes reveal their role in isoniazid and ethionamide resistance in *Mycobacterium smegmatis*. *Antimicrob Agents Chemother* 55:3133–3139. [PubMed: 21502624]
 74. Rawat M, Johnson C, Cadiz V, Av-Gay Y. 2007 Comparative analysis of mutants in the mycothiol biosynthesis pathway in *Mycobacterium smegmatis*. *Biochem Biophys Res Commun* 363:71–76. [PubMed: 17826740]

75. Projahn M, Koser CU, Homolka S, Summers DK, Archer JA, Niemann S. 2011 Polymorphisms in isoniazid and prothionamide resistance genes of the *Mycobacterium tuberculosis* complex. *Antimicrob Agents Chemother* 55:4408–4411. [PubMed: 21709103]
76. Wang XD, Gu J, Wang T, Bi LJ, Zhang ZP, Cui ZQ, Wei HP, Deng JY, Zhang XE. 2011 Comparative analysis of mycobacterial NADH pyrophosphatase isoforms reveals a novel mechanism for isoniazid and ethionamide inactivation. *Mol Microbiol* 82:1375–1391. [PubMed: 22026918]
77. Middlebrook G 1954 Isoniazid resistance and catalase activity of tubercle bacilli. *Am Rev Tuberc* 69:471–472. [PubMed: 13138881]
78. Middlebrook G, Cohn ML. 1953 Some observations on the pathogenicity of isoniazid-resistant variants of tubercle bacilli. *Science* 118:297–299. [PubMed: 13089681]
79. Winder F 1960 Catalase and peroxidase in mycobacteria. Possible relationship to the mode of action of isoniazid. *Am Rev Respir Dis* 81: 68–78. [PubMed: 13845182]
80. Zhang Y, Garbe T, Young D. 1993 Transformation with *katG* restores isoniazid-sensitivity in *Mycobacterium tuberculosis* isolates resistant to a range of drug concentrations. *Mol Microbiol* 8:521–524. [PubMed: 8392139]
81. Mokrousov I, Narvskaya O, Otten T, Limeschenko E, Steklova L, Vyshnevskiy B. 2002 High prevalence of *KatG* Ser315Thr substitution among isoniazid-resistant *Mycobacterium tuberculosis* clinical isolates from northwestern Russia, 1996 to 2001. *Antimicrob Agents Chemother* 46:1417–1424. [PubMed: 11959577]
82. Wengenack NL, Uhl JR, St Amand AL, Tomlinson AJ, Benson LM, Naylor S, Kline BC, Cockerill FR 3rd, Rusnak F. 1997 Recombinant *Mycobacterium tuberculosis* *KatG*(S315T) is a competent catalase-peroxidase with reduced activity toward isoniazid. *J Infect Dis* 176:722–727. [PubMed: 9291321]
83. Saint-Joanis B, Souchon H, Wilming M, Johnsson K, Alzari PM, Cole ST. 1999 Use of site-directed mutagenesis to probe the structure, function and isoniazid activation of the catalase/peroxidase, *KatG*, from *Mycobacterium tuberculosis*. *Biochem J* 338(Pt 3):753–760. [PubMed: 10051449]
84. Ramaswamy S, Musser JM. 1998 Molecular genetic basis of anti-microbial agent resistance in *Mycobacterium tuberculosis*: 1998 update. *Tuber Lung Dis* 79:3–29. [PubMed: 10645439]
85. van Doorn HR, Kuijper EJ, van der Ende A, Welten AG, van Soolingen D, de Haas PE, Dankert J. 2001 The susceptibility of *Mycobacterium tuberculosis* to isoniazid and the Arg→Leu mutation at codon 463 of *katG* are not associated. *J Clin Microbiol* 39:1591–1594. [PubMed: 11283093]
86. van Soolingen D, de Haas PE, van Doorn HR, Kuijper E, Rinder H, Borgdorff MW. 2000 Mutations at amino acid position 315 of the *katG* gene are associated with high-level resistance to isoniazid, other drug resistance, and successful transmission of *Mycobacterium tuberculosis* in the Netherlands. *J Infect Dis* 182:1788–1790. [PubMed: 11069256]
87. Wei CJ, Lei B, Musser JM, Tu SC. 2003 Isoniazid activation defects in recombinant *Mycobacterium tuberculosis* catalase-peroxidase (*KatG*) mutants evident in *InhA* inhibitor production. *Antimicrob Agents Chemother* 47:670–675. [PubMed: 12543676]
88. Ramaswamy SV, Reich R, Dou SJ, Jasperse L, Pan X, Wanger A, Quitugua T, Graviss EA. 2003 Single nucleotide polymorphisms in genes associated with isoniazid resistance in *Mycobacterium tuberculosis*. *Antimicrob Agents Chemother* 47:1241–1250. [PubMed: 12654653]
89. Cohn ML, Oda U, Kovitz C, Middlebrook G. 1954 Studies on isoniazid and tubercle bacilli. I. The isolation of isoniazid-resistant mutants in vitro. *Am Rev Tuberc* 70:465–475. [PubMed: 13189061]
90. Cohn ML, Kovitz C, Oda U, Middlebrook G. 1954 Studies on isoniazid and tubercle bacilli. II. The growth requirements, catalase activities, and pathogenic properties of isoniazid-resistant mutants. *Am Rev Tuberc* 70:641–664. [PubMed: 13197742]
91. Pym AS, Saint-Joanis B, Cole ST. 2002 Effect of *katG* mutations on the virulence of *Mycobacterium tuberculosis* and the implication for transmission in humans. *Infect Immun* 70:4955–4960. [PubMed: 12183541]
92. Gagneux S, Burgos MV, DeRiemer K, Encisco A, Munoz S, Hopewell PC, Small PM, Pym AS. 2006 Impact of bacterial genetics on the transmission of isoniazid-resistant *Mycobacterium tuberculosis*. *PLoS Pathog* 2:e61. [PubMed: 16789833]

93. Escalante P, McKean-Cowdin R, Ramaswamy SV, Williams-Bouyer N, Teeter LD, Jones B, Graviss EA. 2013 Can mycobacterial katG genetic changes in isoniazid-resistant tuberculosis influence human disease features? *Int J Tuberc Lung Dis* 17:641–51.
94. Pym AS, Domenech P, Honore N, Song J, Deretic V, Cole ST. 2001 Regulation of catalase-peroxidase (KatG) expression, isoniazid sensitivity and virulence by furA of *Mycobacterium tuberculosis*. *Mol Microbiol* 40:879–889. [PubMed: 11401695]
95. Zahrt TC, Song J, Siple J, Deretic V. 2001 Mycobacterial FurA is a negative regulator of catalase-peroxidase gene katG. *Mol Microbiol* 39:1174–1185. [PubMed: 11251835]
96. Ando H, Kitao T, Miyoshi-Akiyama T, Kato S, Mori T, Kirikae T. 2011 Downregulation of katG expression is associated with isoniazid resistance in *Mycobacterium tuberculosis*. *Mol Microbiol* 79:1615–1628. [PubMed: 21244531]
97. Lee JH, Ammerman NC, Nolan S, Geiman DE, Lun S, Guo H, Bishai WR. 2012 Isoniazid resistance without a loss of fitness in *Mycobacterium tuberculosis*. *Nat Commun* 3:753. [PubMed: 22434196]
98. Rosner JL. 1993 Susceptibilities of oxyR regulon mutants of *Escherichia coli* and *Salmonella typhimurium* to isoniazid. *Antimicrob Agents Chemother* 37:2251–2253. [PubMed: 8257155]
99. Sreevatsan S, Pan X, Zhang Y, Deretic V, Musser JM. 1997 Analysis of the oxyR-ahpC region in isoniazid-resistant and -susceptible *Mycobacterium tuberculosis* complex organisms recovered from diseased humans and animals in diverse localities. *Antimicrob Agents Chemother* 41:600–606. [PubMed: 9056000]
100. Sherman DR, Mdluli K, Hickey MJ, Arain TM, Morris SL, Barry CE 3rd, Stover CK. 1996 Compensatory ahpC gene expression in isoniazid-resistant *Mycobacterium tuberculosis*. *Science* 272:1641–1643. [PubMed: 8658136]
101. Ng VH, Cox JS, Sousa AO, MacMicking JD, McKinney JD. 2004 Role of KatG catalase-peroxidase in mycobacterial pathogenesis: countering the phagocyte oxidative burst. *Mol Microbiol* 52:1291–1302. [PubMed: 15165233]
102. Baker LV, Brown TJ, Maxwell O, Gibson AL, Fang Z, Yates MD, Drobniewski FA. 2005 Molecular analysis of isoniazid-resistant *Mycobacterium tuberculosis* isolates from England and Wales reveals the phylogenetic significance of the ahpC –46A polymorphism. *Antimicrob Agents Chemother* 49:1455–1464. [PubMed: 15793126]
103. Upton AM, Mushtaq A, Victor TC, Sampson SL, Sandy J, Smith DM, van Helden PV, Sim E. 2001 Arylamine N-acetyltransferase of *Mycobacterium tuberculosis* is a polymorphic enzyme and a site of isoniazid metabolism. *Mol Microbiol* 42:309–317. [PubMed: 11703656]
104. Payton M, Auty R, Delgoda R, Everett M, Sim E. 1999 Cloning and characterization of arylamine N-acetyltransferase genes from *Mycobacterium smegmatis* and *Mycobacterium tuberculosis*: increased expression results in isoniazid resistance. *J Bacteriol* 181:1343–1347. [PubMed: 9973365]
105. Bhakta S, Besra GS, Upton AM, Parish T, Sholto-Douglas-Vernon C, Gibson KJ, Knutton S, Gordon S, DaSilva RP, Anderton MC, Sim E. 2004 Arylamine N-acetyltransferase is required for synthesis of mycolic acids and complex lipids in *Mycobacterium bovis* BCG and represents a novel drug target. *J Exp Med* 199:1191–1199. [PubMed: 15117974]
106. Alland D, Kramnik I, Weisbrod TR, Otsubo L, Cerny R, Miller LP, Jacobs WR Jr, Bloom BR. 1998 Identification of differentially expressed mRNA in prokaryotic organisms by customized amplification libraries (DECAL): the effect of isoniazid on gene expression in *Mycobacterium tuberculosis*. *Proc Natl Acad Sci USA* 95:13227–13232. [PubMed: 9789070]
107. Cole ST, Brosch R, Parkhill J, Garnier T, Churcher C, Harris D, Gordon SV, Eiglmeier K, Gas S, Barry CE 3rd, Tekaia F, Badcock K, Basham D, Brown D, Chillingworth T, Connor R, Davies R, Devlin K, Feltwell T, Gentles S, Hamlin N, Holroyd S, Hornsby T, Jagels K, Krogh A, McLean J, Moule S, Murphy L, Oliver K, Osborne J, Quail MA, Rajandream MA, Rogers J, Rutter S, Seeger K, Skelton J, Squares R, Squares S, Sulston JE, Taylor K, Whitehead S, Barrell BG. 1998 Deciphering the biology of *Mycobacterium tuberculosis* from the complete genome sequence. *Nature* 393:537–544. [PubMed: 9634230]
108. Wilson M, DeRisi J, Kristensen HH, Imboden P, Rane S, Brown PO, Schoolnik GK. 1999 Exploring drug-induced alterations in gene expression in *Mycobacterium tuberculosis* by microarray hybridization. *Proc Natl Acad Sci USA* 96:12833–12838. [PubMed: 10536008]

109. Mdluli K, Slayden RA, Zhu Y, Ramaswamy S, Pan X, Mead D, Crane DD, Musser JM, Barry CE 3rd. 1998 Inhibition of a Mycobacterium tuberculosis beta-ketoacyl ACP synthase by isoniazid. *Science* 280:1607–1610. [PubMed: 9616124]
110. Kremer L, Dover LG, Morbidoni HR, Vilcheze C, Maughan WN, Baulard A, Tu S, Honore N, Deretic V, Sacchettini JC, Locht C, Jacobs WRJ, Besra G. 2003 Inhibition of InhA activity, but not KasA activity, induces formation of a KasA-containing complex in mycobacteria. *J Biol Chem* 278:20547–20554. [PubMed: 12654922]
111. Colangeli R, Helb D, Sridharan S, Sun J, Varma-Basil M, Hazbon MH, Harbacheuski R, Megjugorac NJ, Jacobs WR Jr, Holzenburg A, Sacchettini JC, Alland D. 2005 The Mycobacterium tuberculosis *iniA* gene is essential for activity of an efflux pump that confers drug tolerance to both isoniazid and ethambutol. *Mol Microbiol* 55:1829–1840. [PubMed: 15752203]
112. Alland D, Steyn AJ, Weisbrod T, Aldrich K, Jacobs WR Jr. 2000 Characterization of the Mycobacterium tuberculosis *iniBAC* promoter, a promoter that responds to cell wall biosynthesis inhibition. *J Bacteriol* 182:1802–1811. [PubMed: 10714983]
113. Chen P, Bishai WR. 1998 Novel selection for isoniazid (INH) resistance genes supports a role for NAD⁺-binding proteins in mycobacterial INH resistance. *Infect Immun* 66:5099–5106. [PubMed: 9784509]
114. Ducasse-Cabanot S, Cohen-Gonsaud M, Marrakchi H, Nguyen M, Zerbib D, Bernadou J, Daffe M, Labesse G, Quemard A. 2004 In vitro inhibition of the Mycobacterium tuberculosis beta-ketoacyl-acyl carrier protein reductase MabA by isoniazid. *Antimicrob Agents Chemother* 48:242–249. [PubMed: 14693546]
115. Argyrou A, Vetting MW, Aladegbami B, Blanchard JS. 2006 Mycobacterium tuberculosis dihydrofolate reductase is a target for isoniazid. *Nat Struct Mol Biol* 13:408–413. [PubMed: 16648861]
116. Wang F, Jain P, Gulten G, Liu Z, Feng Y, Ganesula K, Motiwala AS, Ioerger TR, Alland D, Vilcheze C, Jacobs WR Jr, Sacchettini JC. 2010 Mycobacterium tuberculosis dihydrofolate reductase is not a target relevant to the antitubercular activity of isoniazid. *Antimicrob Agents Chemother* 54:3776–3782. [PubMed: 20566771]
117. Ho YM, Sun YJ, Wong SY, Lee AS. 2009 Contribution of *dfrA* and *inhA* mutations to the detection of isoniazid-resistant Mycobacterium tuberculosis isolates. *Antimicrob Agents Chemother* 53:4010–4012. [PubMed: 19581462]
118. Argyrou A, Jin L, Siconilfi-Baez L, Angeletti RH, Blanchard JS. 2006 Proteome-wide profiling of isoniazid targets in Mycobacterium tuberculosis. *Biochemistry* 45:13947–13953. [PubMed: 17115689]
119. McMurry L, Petrucci RE Jr, Levy SB. 1980 Active efflux of tetracycline encoded by four genetically different tetracycline resistance determinants in Escherichia coli. *Proc Natl Acad Sci USA* 77:3974–3977. [PubMed: 7001450]
120. Ainsa JA, Blokpoel MC, Otal I, Young DB, De Smet KA, Martin C. 1998 Molecular cloning and characterization of Tap, a putative multi-drug efflux pump present in Mycobacterium fortuitum and Mycobacterium tuberculosis. *J Bacteriol* 180:5836–5843. [PubMed: 9811639]
121. Silva PE, Bigi F, Santangelo MP, Romano MI, Martin C, Cataldi A, Ainsa JA. 2001 Characterization of P55, a multidrug efflux pump in Mycobacterium bovis and Mycobacterium tuberculosis. *Antimicrob Agents Chemother* 45:800–804. [PubMed: 11181364]
122. Gupta AK, Katoch VM, Chauhan DS, Sharma R, Singh M, Venkatesan K, Sharma VD. 2010 Microarray analysis of efflux pump genes in multidrug-resistant Mycobacterium tuberculosis during stress induced by common anti-tuberculous drugs. *Microb Drug Resist* 16:21–28. [PubMed: 20001742]
123. Wang K, Pei H, Huang B, Zhu X, Zhang J, Zhou B, Zhu L, Zhang Y, Zhou FF. 2013 The expression of ABC efflux pump, Rv1217c-Rv1218c, and its association with multidrug resistance of Mycobacterium tuberculosis in China. *Curr Microbiol* 66:222–226. [PubMed: 23143285]
124. Balganes M, Kuruppath S, Marcel N, Sharma S, Nair A, Sharma U. 2010 Rv1218c, an ABC transporter of Mycobacterium tuberculosis with implications in drug discovery. *Antimicrob Agents Chemother* 54:5167–5172. [PubMed: 20921309]

125. Domenech P, Reed MB, Barry CE 3rd. 2005 Contribution of the Mycobacterium tuberculosis MmpL protein family to virulence and drug resistance. *Infect Immun* 73:3492–3501. [PubMed: 15908378]
126. Li XZ, Zhang L, Nikaido H. 2004 Efflux pump-mediated intrinsic drug resistance in Mycobacterium smegmatis. *Antimicrob Agents Chemother* 48:2415–2423. [PubMed: 15215089]
127. Pasca MR, Guglielame P, De Rossi E, Zara F, Riccardi G. 2005 mmpL7 gene of Mycobacterium tuberculosis is responsible for isoniazid efflux in Mycobacterium smegmatis. *Antimicrob Agents Chemother* 49: 4775–4777. [PubMed: 16251328]
128. Hillemann D, Rusch-Gerdes S, Richter E. 2007 Evaluation of the GenoType MTBDRplus assay for rifampin and isoniazid susceptibility testing of Mycobacterium tuberculosis strains and clinical specimens. *J Clin Microbiol* 45:2635–2640. [PubMed: 17537937]
129. Hartkoorn RC, Sala C, Neres J, Pojer F, Magnet S, Mukherjee R, Uplekar S, Boy-Rottger S, Altmann KH, Cole ST. 2012 Towards a new tuberculosis drug: pyridomycin: nature's isoniazid. *EMBO Mol Med* 4:1032–1042. [PubMed: 22987724]
130. Valvatne H, Syre H, Kross M, Stavrum R, Ti T, Phyu S, Grewal HM. 2009 Isoniazid and rifampicin resistance-associated mutations in Mycobacterium tuberculosis isolates from Yangon, Myanmar: implications for rapid molecular testing. *J Antimicrob Chemother* 64:694–701. [PubMed: 19710078]
131. Caws M, Duy PM, Tho DQ, Lan NT, Hoa DV, Farrar J. 2006 Mutations prevalent among rifampin- and isoniazid-resistant Mycobacterium tuberculosis isolates from a hospital in Vietnam. *J Clin Microbiol* 44:2333–2337. [PubMed: 16825345]
132. Rindi L, Bianchi L, Tortoli E, Lari N, Bonanni D, Garzelli C. 2005 Mutations responsible for Mycobacterium tuberculosis isoniazid resistance in Italy. *Int J Tuberc Lung Dis* 9:94–97. [PubMed: 15675557]
133. Huang WL, Chen HY, Kuo YM, Jou R. 2009 Performance assessment of the GenoType MTBDRplus test and DNA sequencing in detection of multidrug-resistant Mycobacterium tuberculosis. *J Clin Microbiol* 47:2520–2524. [PubMed: 19494067]
134. Fenner L, Egger M, Bodmer T, Altpeter E, Zwahlen M, Jaton K, Pfyffer GE, Borrell S, Dubuis O, Bruderer T, Siegrist HH, Furrer H, Calmy A, Fehr J, Stalder JM, Ninet B, Bottger EC, Gagneux S. 2012 Effect of mutation and genetic background on drug resistance in Mycobacterium tuberculosis. *Antimicrob Agents Chemother* 56:3047–3053. [PubMed: 22470121]
135. Zhang M, Yue J, Yang YP, Zhang HM, Lei JQ, Jin RL, Zhang XL, Wang HH. 2005 Detection of mutations associated with isoniazid resistance in Mycobacterium tuberculosis isolates from China. *J Clin Microbiol* 43:5477–5482. [PubMed: 16272473]
136. Luo T, Zhao M, Li X, Xu P, Gui X, Pickerill S, DeRiemer K, Mei J, Gao Q. 2010 Selection of mutations to detect multidrug-resistant Mycobacterium tuberculosis strains in Shanghai, China. *Antimicrob Agents Chemother* 54:1075–1081. [PubMed: 20008778]
137. Doustdar F, Khosravi AD, Farnia P, Masjedi MR, Velayati AA. 2008 Molecular analysis of isoniazid resistance in different genotypes of Mycobacterium tuberculosis isolates from Iran. *Microb Drug Resist* 14: 273–279. [PubMed: 19090721]
138. Rahim Z, Nakajima C, Raqib R, Zaman K, Endtz HP, van der Zanden AG, Suzuki Y. 2012 Molecular mechanism of rifampicin and isoniazid resistance in Mycobacterium tuberculosis from Bangladesh. *Tuberculosis (Edinb)* 92:529–534. [PubMed: 22863574]
139. Cardoso RF, Cooksey RC, Morlock GP, Barco P, Cecon L, Forestiero F, Leite CQ, Sato DN, Shikama Mde L, Mamizuka EM, Hirata RD, Hirata MH. 2004 Screening and characterization of mutations in isoniazid-resistant Mycobacterium tuberculosis isolates obtained in Brazil. *Antimicrob Agents Chemother* 48:3373–3381. [PubMed: 15328099]
140. Kiepiela P, Bishop KS, Smith AN, Roux L, York DF. 2000 Genomic mutations in the katG, inhA and aphC genes are useful for the prediction of isoniazid resistance in Mycobacterium tuberculosis isolates from Kwazulu Natal, South Africa. *Tuber Lung Dis* 80:47–56. [PubMed: 10897383]
141. Rouse DA, Li Z, Bai GH, Morris SL. 1995 Characterization of the katG and inhA genes of isoniazid-resistant clinical isolates of Mycobacterium tuberculosis. *Antimicrob Agents Chemother* 39:2472–2477. [PubMed: 8585728]

142. Guo H, Seet Q, Denkin S, Parsons L, Zhang Y. 2006 Molecular characterization of isoniazid-resistant clinical isolates of *Mycobacterium tuberculosis* from the USA. *J Med Microbiol* 55:1527–1531. [PubMed: 17030912]
143. Lavender C, Globan M, Sievers A, Billman-Jacobe H, Fyfe J. 2005 Molecular characterization of isoniazid-resistant *Mycobacterium tuberculosis* isolates collected in Australia. *Antimicrob Agents Chemother* 49:4068–4074. [PubMed: 16189082]
144. Silva MS, Senna SG, Ribeiro MO, Valim AR, Telles MA, Kritski A, Morlock GP, Cooksey RC, Zaha A, Rossetti ML. 2003 Mutations in *katG*, *inhA*, and *ahpC* genes of Brazilian isoniazid-resistant isolates of *Mycobacterium tuberculosis*. *J Clin Microbiol* 41:4471–4474. [PubMed: 12958298]
145. Poudel A, Nakajima C, Fukushima Y, Suzuki H, Pandey BD, Maharjan B, Suzuki Y. 2012 Molecular characterization of multidrug-resistant *Mycobacterium tuberculosis* isolated in Nepal. *Antimicrob Agents Chemother* 56:2831–2836. [PubMed: 22450970]
146. Sekiguchi J, Miyoshi-Akiyama T, Augustynowicz-Kopec E, Zwolska Z, Kirikae F, Toyota E, Kobayashi I, Morita K, Kudo K, Kato S, Kuratsuji T, Mori T, Kirikae T. 2007 Detection of multidrug resistance in *Mycobacterium tuberculosis*. *J Clin Microbiol* 45:179–192. [PubMed: 17108078]
147. N'Guessan KR, Dosso M, Ekaza E, Kouakou J, Jarlier V. 2008 Molecular characterisation of isoniazid-resistant *Mycobacterium tuberculosis* isolated from new cases in Lagunes region (Cote d'Ivoire). *Int J Antimicrob Agents* 31:498–500. [PubMed: 18313272]
148. Lin HL, Kim H, Yun Y, Park CG, Kim B, Park Y, Kook Y. 2007 Mutations of *katG* and *inhA* in MDR *M. tuberculosis*. *Tuberc Respir Dis* 63:128–138.
149. Basso LA, Zheng R, Musser JM, Jacobs WR Jr, Blanchard JS. 1998 Mechanisms of isoniazid resistance in *Mycobacterium tuberculosis*: enzymatic characterization of enoyl reductase mutants identified in isoniazid-resistant clinical isolates. *J Infect Dis* 178:769–775. [PubMed: 9728546]
150. Sholto-Douglas-Vernon C, Sandy J, Victor TC, Sim E, Helden PD. 2005 Mutational and expression analysis of *tbnat* and its response to isoniazid. *J Med Microbiol* 54:1189–1197. [PubMed: 16278433]
151. Ristow M, Mohlig M, Rifai M, Schatz H, Feldmann K, Pfeiffer A. 1995 New isoniazid/ethionamide resistance gene mutation and screening for multidrug-resistant *Mycobacterium tuberculosis* strains. *Lancet* 346:502–503.
152. Yoon JH, Nam JS, Kim KJ, Choi Y, Lee H, Cho SN, Ro YT. 2012 Molecular characterization of drug-resistant and -susceptible *Mycobacterium tuberculosis* isolated from patients with tuberculosis in Korea. *Diagn Microbiol Infect Dis* 72:52–61. [PubMed: 22078903]
153. Chan RC, Hui M, Chan EW, Au TK, Chin ML, Yip CK, AuYeang CK, Yeung CY, Kam KM, Yip PC, Cheng AF. 2007 Genetic and phenotypic characterization of drug-resistant *Mycobacterium tuberculosis* isolates in Hong Kong. *J Antimicrob Chemother* 59:866–873. [PubMed: 17360809]
154. Leung KL, Yip CW, Yeung YL, Wong KL, Chan WY, Chan MY, Kam KM. 2010 Usefulness of resistant gene markers for predicting treatment outcome on second-line anti-tuberculosis drugs. *J Appl Microbiol* 109:2087–2094. [PubMed: 20854453]
155. Boonaiam S, Chairprasert A, Prammananan T, Leechawengwongs M. 2010 Genotypic analysis of genes associated with isoniazid and ethionamide resistance in MDR-TB isolates from Thailand. *Clin Microbiol Infect* 16:396–399. [PubMed: 19486070]
156. Lee H, Cho SN, Bang HE, Lee JH, Bai GH, Kim SJ, Kim JD. 2000 Exclusive mutations related to isoniazid and ethionamide resistance among *Mycobacterium tuberculosis* isolates from Korea. *Int J Tuberc Lung Dis* 4:441–447. [PubMed: 10815738]
157. Marttila HJ, Soini H, Huovinen P, Viljanen MK. 1996 *katG* mutations in isoniazid-resistant *Mycobacterium tuberculosis* isolates recovered from Finnish patients. *Antimicrob Agents Chemother* 40:2187–2189. [PubMed: 8878604]
158. Khanna A, Raj VS, Tarai B, Sood R, Pareek PK, Upadhyay DJ, Sharma P, Rattan A, Saini KS, Singh H. 2010 Emergence and molecular characterization of extensively drug-resistant *Mycobacterium tuberculosis* clinical isolates from the Delhi Region in India. *Antimicrob Agents Chemother* 54:4789–4793. [PubMed: 20713679]

159. Ramaswamy SV, Dou SJ, Rendon A, Yang Z, Cave MD, Graviss EA. 2004 Genotypic analysis of multidrug-resistant *Mycobacterium tuberculosis* isolates from Monterrey, Mexico. *J Med Microbiol* 53:107–113. [PubMed: 14729930]
160. Siddiqi N, Shamim M, Hussain S, Choudhary RK, Ahmed N, Prachee, Banerjee S, Savithri GR, Alam M, Pathak N, Amin A, Hanief M, Katoch VM, Sharma SK, Hasnain SE. 2002 Molecular characterization of multidrug-resistant isolates of *Mycobacterium tuberculosis* from patients in North India. *Antimicrob Agents Chemother* 46:443–450. [PubMed: 11796356]
161. Torres MJ, Criado A, Gonzalez N, Palomares JC, Aznar J. 2002 Rifampin and isoniazid resistance associated mutations in *Mycobacterium tuberculosis* clinical isolates in Seville, Spain. *Int J Tuberc Lung Dis* 6:160–163. [PubMed: 11931416]
162. Pretorius GS, van Helden PD, Sirgel F, Eisenach KD, Victor TC. 1995 Mutations in *katG* gene sequences in isoniazid-resistant clinical isolates of *Mycobacterium tuberculosis* are rare. *Antimicrob Agents Chemother* 39:2276–2281. [PubMed: 8619582]
163. Cockerill FR 3rd, Uhl JR, Temesgen Z, Zhang Y, Stockman L, Roberts GD, Williams DL, Kline BC. 1995 Rapid identification of a point mutation of the *Mycobacterium tuberculosis* catalase-peroxidase (*katG*) gene associated with isoniazid resistance. *J Infect Dis* 171:240–245. [PubMed: 7798673]
164. Ghiladi RA, Medzihradzky KF, Rusnak FM, Ortiz de Montellano PR. 2005 Correlation between isoniazid resistance and superoxide reactivity in *Mycobacterium tuberculosis* *KatG*. *J Am Chem Soc* 127:13428–13442. [PubMed: 16173777]
165. Bolotin S, Alexander DC, Chedore P, Drews SJ, Jamieson F. 2009 Molecular characterization of drug-resistant *Mycobacterium tuberculosis* isolates from Ontario, Canada. *J Antimicrob Chemother* 64:263–266. [PubMed: 19520719]
166. Mo L, Zhang W, Wang J, Weng XH, Chen S, Shao LY, Pang MY, Chen ZW. 2004 Three-dimensional model and molecular mechanism of *Mycobacterium tuberculosis* catalase-peroxidase (*KatG*) and isoniazid-resistant *KatG* mutants. *Microb Drug Resist* 10:269–279. [PubMed: 15650370]
167. Ando H, Kondo Y, Suetake T, Toyota E, Kato S, Mori T, Kirikae T. 2010 Identification of *katG* mutations associated with high-level isoniazid resistance in *Mycobacterium tuberculosis*. *Antimicrob Agents Chemother* 54:1793–1799. [PubMed: 20211896]
168. Jnawali HN, Hwang SC, Park YK, Kim H, Lee YS, Chung GT, Choe KH, Ryoo S. 2013 Characterization of mutations in multi- and extensive drug resistance among strains of *Mycobacterium tuberculosis* clinical isolates in Republic of Korea. *Diagn Microbiol Infect Dis* 76:187–196. [PubMed: 23561273]
169. Doustdar F, Khosravi AD, Farnia P, Masjedi MR, Velayati AA. 2008 Molecular analysis of isoniazid resistance in different genotypes of *Mycobacterium tuberculosis* isolates from Iran. *Microb Drug Resist* 14:273–279. [PubMed: 19090721]
170. Rouse DA, DeVito JA, Li Z, Byer H, Morris SL. 1996 Site-directed mutagenesis of the *katG* gene of *Mycobacterium tuberculosis*: effects on catalase-peroxidase activities and isoniazid resistance. *Mol Microbiol* 22:583–592. [PubMed: 8939440]
171. Heym B, Alzari PM, Honore N, Cole ST. 1995 Missense mutations in the catalase-peroxidase gene, *katG*, are associated with isoniazid resistance in *Mycobacterium tuberculosis*. *Mol Microbiol* 15:235–245. [PubMed: 7746145]
172. Yuan X, Zhang T, Kawakami K, Zhu J, Li H, Lei J, Tu S. 2012 Molecular characterization of multidrug- and extensively drug-resistant *Mycobacterium tuberculosis* strains in Jiangxi, China. *J Clin Microbiol* 50:2404–2413. [PubMed: 22553245]
173. Ramirez MV, Cowart KC, Campbell PJ, Morlock GP, Sikes D, Winchell JM, Posey JE. 2010 Rapid detection of multidrug-resistant *Mycobacterium tuberculosis* by use of real-time PCR and high-resolution melt analysis. *J Clin Microbiol* 48:4003–4009. [PubMed: 20810777]
174. Fang Z, Doig C, Rayner A, Kenna DT, Watt B, Forbes KJ. 1999. Molecular evidence for heterogeneity of the multiple-drug-resistant *Mycobacterium tuberculosis* population in Scotland (1990 to 1997). *J Clin Microbiol* 37:998–1003.
175. Abe C, Kobayashi I, Mitarai S, Wada M, Kawabe Y, Takashima T, Suzuki K, Sng LH, Wang S, Htay HH, Ogata H. 2008 Biological and molecular characteristics of *Mycobacterium tuberculosis*

- clinical isolates with low-level resistance to isoniazid in Japan. *J Clin Microbiol* 46:2263–2268. [PubMed: 18508939]
176. Khadka DK, Eampokalap B, Panitchakorn J, Ramasoota P, Khusmith S. 2007 Multiple mutations in *katG* and *inhA* identified in Thai isoniazid-resistant *Mycobacterium tuberculosis* isolates. *Southeast Asian J Trop Med Public Health* 38:376–382. [PubMed: 17539290]
177. Kim SY, Park YJ, Kim WI, Lee SH, Ludgerus Chang C, Kang SJ, Kang CS. 2003 Molecular analysis of isoniazid resistance in *Mycobacterium tuberculosis* isolates recovered from South Korea. *Diagn Microbiol Infect Dis* 47:497–502. [PubMed: 14596968]
178. Minh NN, Van Bac N, Son NT, Lien VT, Ha CH, Cuong NH, Mai CT, Le TH. 2012 Molecular characteristics of rifampin- and isoniazid-resistant *Mycobacterium tuberculosis* strains isolated in Vietnam. *J Clin Microbiol* 50:598–601. [PubMed: 22170905]
179. Zakerbostanabad S, Titov LP, Bahrmand AR. 2008 Frequency and molecular characterization of isoniazid resistance in *katG* region of MDR isolates from tuberculosis patients in southern endemic border of Iran. *Infect Genet Evol* 8:15–19. [PubMed: 17988957]
180. Zenteno-Cuevas R, Zenteno JC, Cuellar A, Cuevas B, Sampieri CL, Riviera JE, Parissi A. 2009 Mutations in *rpoB* and *katG* genes in *Mycobacterium* isolates from the Southeast of Mexico. *Mem Inst Oswaldo Cruz* 104:468–472. [PubMed: 19547874]
181. Soudani A, Hadjfredj S, Zribi M, Messaadi F, Messaoud T, Masmoudi A, Fendri C. 2011 Genotypic and phenotypic characteristics of Tunisian isoniazid-resistant *Mycobacterium tuberculosis* strains. *J Microbiol* 49:413–417. [PubMed: 21717327]
182. Haas WH, Schilke K, Brand J, Amthor B, Weyer K, Fourie PB, Bretzel G, Sticht-Groh V, Bremer HJ. 1997 Molecular analysis of *katG* gene mutations in strains of *Mycobacterium tuberculosis* complex from Africa. *Antimicrob Agents Chemother* 41:1601–1603. [PubMed: 9210694]
183. Musser JM, Kapur V, Williams DL, Kreiswirth BN, van Soolingen D, van Embden JD. 1996 Characterization of the catalase-peroxidase gene (*katG*) and *inhA* locus in isoniazid-resistant and -susceptible strains of *Mycobacterium tuberculosis* by automated DNA sequencing: restricted array of mutations associated with drug resistance. *J Infect Dis* 173:196–202. [PubMed: 8537659]
184. Lipin MY, Stepanshina VN, Shemyakin IG, Shinnick TM. 2007 Association of specific mutations in *katG*, *rpoB*, *rpsL* and *rrs* genes with spoligotypes of multidrug-resistant *Mycobacterium tuberculosis* isolates in Russia. *Clin Microbiol Infect* 13:620–626. [PubMed: 17403134]
185. Waksman SA. 1964 *The Conquest of Tuberculosis*. University of California Press, Berkeley.
186. Winder FG, Collins PB. 1970 Inhibition by isoniazid of synthesis of mycolic acids in *Mycobacterium tuberculosis*. *J Gen Microbiol* 63: 41–48. [PubMed: 5500025]






FIGURE 1. Early synthetic antituberculosis drugs. doi:10.1128/microbiolspec.MGM2-0014-2013.f1

**FIGURE 2.**

Mechanism of action of INH and ETH. INH and ETH are activated by the catalase peroxidase KatG and monooxygenase EthA, respectively, to form a reactive species that binds to NAD⁺. The resulting adducts, INH-NAD or ETH-NAD, inhibit the enoyl-ACP reductase InhA of the FASII system, resulting in mycolic acid biosynthesis inhibition. doi:

[10.1128/microbiolspec.MGM2-0014-2013.f2](https://doi.org/10.1128/microbiolspec.MGM2-0014-2013.f2)

**FIGURE 3.**

Relationship among the genes and proteins involved in the resistance to INH and ETH in *M. tuberculosis*. Connections in red indicate a negative relationship (degradation of an active molecule, negative regulator of an enzyme) that would lead to resistance to INH and/or ETH; in green are positive actions that would increase a strain fitness or susceptibility to the drugs. The dashed line points to an interaction that does not result directly in INH resistance or susceptibility. doi:10.1128/microbiolspec.MGM2-0014-2013.f3

TABLE 1
Identified mutations in genes other than *katG* in INH-resistant *M. tuberculosis* strains^a

<i>oxyR'-ahpC</i> intergenic region	<i>furA-katG</i> intergenic region	<i>Ndh</i>
t-89a (130)	c-1 ins (102)	R13C (67)
g-88a (130)	g-7a (96)	V18A* (66–67)
c-81t (131)	a-10c (96)	T110A (68)
g-74a (132)	g-12a (96)	R268H (66, 68)
c-72t (131)		G313R* (116)
g-67a (66)	<i>fabG-inhA</i> regulatory region	<i>iniB</i>
g-66a (133)	g-147t (88)	t198ins (135)
atgt-54 ins (92)	a-113c (134)	a211del (135)
c-54t (132)	g-102a (134)	222 12bp del (88)
c-52t (136)	a-92t (69)	N88S* (116)
g-51a (131)	g-67c (137)	G192* (135)
t-49g (137)	g-47c.a (134, 138)	H481Q* (116)
g-48a (135, 139)	c-34t (138)	
g-46a* (102, 140)	t-24g (141)	<i>iniA</i>
g-46 del* (66)	g-22c (142)	P3A (88)
c-45t (84)	g-17t* (66, 135, 139, 143)	nt282–286 del (88)
t-44a (99)	a-16g (84)	H481Q* (88, 135)
t-40c (144)	c-15t (66, 88, 135, 139, 140, 143)	R537H (88, 135)
c-39t (66, 135, 139, 140, 144)	t-12a (145)	
t-34c.a (102, 140)	a-11t (66)	
t34 del (102)	t-8a*-g.c (66, 88, 140–142)	<i>iniC</i>
g-32a (140)	t-5a (146)	t79ins (135)
c-30t (66, 144)	c-4a (140)	a98ins (135)
c-20t* (102)	A5P (137)	W83G (88)
c-15t (66, 135, 139, 144)	V14L (137)	
c-12t (66, 135, 139, 140)	T21A (66)	<i>Rv0340</i>
c-10a.g.t (66, 135, 139, 140)		T143* (135)
g-9a* (66, 135, 139, 140, 144)	<i>inhA</i> ORF	G149* (135)

g-6a (66, 140, 144) a-4g (140)	MIL (147) K8N (148) I16T (149)	V163I (88, 135)
ahpC ORF		nat
P2S (69)	I21T,V (66, 88, 135, 139, 149) I25T (136)	G67R* (88) Y177H (150) G207R* (88, 103)
L3K (140)	I47T* (66,149)	
L4R (130)	V78A (149)	Rv1592c
T5I (66)	S94A (59, 66,144)	P42L (88)
F10I (144)	I95P (151)	V430A (88)
D33N (84)	A190S (152)	fadE24
D73H* (66)	I194T* (66, 88)	-64.2 bp ins (88)
E76K (153)	R202G (133)	a-23c* (88)
L191K (66)	E217D (133) T241M (142) T253A* (152)	
oxyR'	D256N (152)	Rv1772
G12a (130)	I258T,V (135, 152)	T4A (88)
g18a (69)	Y259H (152)	
g27t (69)		efpA
c28a (69)		T15R* (116)
c37t (99)	kasA	I73T* (135)
bp67 ins gscg (99)	D66N* (66, 109)	Q513R (116)
g325t (99)	M77I* (88, 135)	E520V (135)
a331c (99)	R121K (69) L245R (135)	fabD
furA	G269S* (66, 69, 88, 109, 135,139)	S275N* (88)
S5P (88, 135)	G312S* (66, 69, 109, 135)	A199T* (88)
c34 del (96)	S34I* (135)	accD6
A14Y (96)	G387D (69)	D229G* (88)
A46Y* (116)	F413L (109)	
L68F (94)	srmR homolog	
C97Y (94)	D3G (88)	fbpC
	M323T* (88)	G158S* (88)

^a Asterisk (*), found in INH-resistant and/or INH-sensitive strains.

Author Manuscript

Author Manuscript

Author Manuscript

Author Manuscript

TABLE 2

Identified mutations in ETH-resistant *M. tuberculosis* strains^a

<i>ethA</i>	<i>ethA</i>	<i>ethA</i>
MIR (62)	A234D (154)	C403G (62)
I9T (154)	t703 del (61)	R404L (154)
G11A (62)	Q246STOP (61)	G413D (61)
g32 del (154)	A248D (154)	c1254 del (154)
A20 ins (62)	Y250STOP (154)	g1268 del (154)
a65 del (46)	cg754 ins (62)	c1290 del (61, 154)
H22P (62)	Q254P (154)	gc1322,1323 del (61)
Y32D (154)	Q254STOP (154)	T453I (154)
a110 del (61, 154)	g768 del (61)*	Y461H (62)
G43S (61), C (46)	S266R (62)	R463D (61)
T44N (154)	Q269STOP (62)	a1391 ins (62)
D49A (155)	Q271STOP (154)	<i>fabG-inhA</i> regulatory region
Y50C (154)	L272P (62)	g-17t (61)
P51L (46)	P288R (154)	c-15t (38, 61, 156)
D55A (61)	Q291STOP (154)	<i>inhA</i> ORF
D58A (46)	R292STOP (154)	I21T(61)
T61M (62)	C294F (154)	S94A (61)
Y84D (46)	F302L (154)	I95P (151)
1bp271 del (46)	T324 ins (154)	<i>mshA</i>
cg282-283 del (154)	L328M (155)	N111S* (62, 70)
g337 del (154)	S329L (62)	Q128STOP ^d (70)
a338 ins (61)	L333R (155)	V171G(62)
a342 del (154)	I338S (61)*	A187V(62)
G124D (62)	T342K (46)	R273C ^b (70)
G139S (154)	d1029 del (154)	
Y140 STOP (154)	N345K (155) (154)	
Q165P (62)	A352P (154)	

Author Manuscript

Author Manuscript

Author Manuscript

Author Manuscript

W167STOP (154)	g1054 del (154)	G299C ^b (70)
T186K (46)	P378L (154)	Q331STOP ^b (70)
g593 del (154)	A381P (46)	G356D ^b (Z0)
c613 del (155)	t1152 del (154)	E361A ^b (70)
g1638–639 del (155)	G385D (61)	<i>ethR</i>
D219G (154)	Y386C (62)	A95T (62)
E223K (61)	S390F (154)	F110L (62)
g673 ins (154)	W391STOP (154)	
tc675 ins (62)	T392A (61)	
T232A (155)	L397R (155)	

^a Asterisk (*), also found in ETH-sensitive strains.

^b Mutations found in *in vitro* cultures.

TABLE 3

Identified *katG* mutations in INH-resistant *M. tuberculosis* strains^a

Complete deletion (30, 88, 134, 141, 157)	E217G,del (84, 158)	W397Y (88) STOP (66)
Partial deletion (138, 159–161)	N218K (153)	A409D,R,T,V (142,152, 153, 162)
V1A (84) L (92)	Q224E (163)	Y413H (133)
P2S (163)	Y229F (164)	K414N (165)
aI7 ins (139)	V230A (153)	R418Q (166)
c30 del (160)	P232R,S (139, 167)	D419A,Y,E, H (59,139)
T11A (160)	G234E (102) R (155)	M420T (167)
T12P (160)	N236T (153)	A424E V (163)
S17N (163)	A243S (163)	G428R (168)
G19D (163)	A245V* (146)	P429S (163)
a98ins (160)	R249C (159)	c1297 ins, c1305 del (167)
N35D (160)	T251M (92)	Q434stop (88)
g109del (160)	F252L (84)	tI311 ins (139)
W38stop (66)	R254L (139)	W438R (88)
L48Q (146)	M257I,T (143, 146)	aI329 ins (139)
aI49 del (102)	N258S (163)	cI339 del (139)
A61T (160)	E261Q (142)	L449F (169)
c185 ins (160)	T262R (84, 141)	S457I (165)
D63E (88, 141)	A264T,V* (152,163)	K459STOP (168)
A65T (163)	H270Q (170)	R463L* (85, 141, 162,171)
A65 or cccc ins (84,157)	T271P (172)	W477stop (84)
A66P (163)	G273C,S (139, 173)	R484S (102)
I71N (84)	T275A,P (84, 159, 162,171)	G485V (84)
D72G (153) K (66)	G279D, A* (59, 139)	K488N (157)
D73N (160)	P280H,L*,P (92, 93,152)	R489S (167)
D74Y, G (153)	A281V (163)	G490S (102, 139)
M84I (153)	G285C,D,V (116, 145, 152)	G491C (135, 143)
T85P (92)	E289D (153)	N493H (142)
Q88R (157)	A291P,V (152, 174)	G494D (59)

Author Manuscript

Author Manuscript

Author Manuscript

Author Manuscript

W90R (139) STOP (88, 135, 163)	L293V (139)	R496L (168)
W91R (88)	Q295K,P,STOP (130, 146, 157)	P501A (157)
D94A (84)	M296V (145)	W505S (175), R (163)
G96C (153)	Q297V (146)	D511del (84)
H97R (139)	G299S (139) C (153) A (133)	D513del (84)
G99E (84)	W300D,G,C,STOP (69, 84, 138, 157)	R515C (66, 84, 135)
R104L (141), Q (92)	gc900 ins (138)	L521del (84)
M105I (93)	S302R (139, 163)	Q525P (84)
A106V (92)	Y304S (165)	N529D (88)
W107R (92)	T308P (176)	D542H (167)
W107STOP (102)	G309C,S,V (177-179)	L546P (172)
H108E,Q (84, 141)	D311E (180) G (153) Y (179)	A550D (163)
A109V (139)	A312G,V (152)	E553K (59)
A110V (59, 84)	S315T,N,I,R,G,L (59, 66, 84, 88, 135, 139, 141-144, 157)	c1667del (66)
D117A (143)	G316D, S* (66)	F567S (84)
G120del (84)	I317L (153)	D573N (92)
G121C (92) V (157)	E318G,V (152, 180)	A574V (84) E (66)
A122del (84)	W321G (66) R (153)	L587L,M,P* (66, 84)
G123E (167)	T322AI (136, 179)	P589T (163)
g371 del (167)	T324A,P (146, 179)	G593D (84)
G125C (153)	T326D (181)	R595stop (59)
H125 ins (171)	K327I (178)	E607K (92)
M126I (163)	W328L,C,F,S,G (84, 155, 172,182,183)	M609I (163)
Q127E,P (153, 167)	D329A,C (138, 145)	L617del (84)
R128P (66) E (174)	S331C (180)	ac1849 ins (157)
F129S (116)	I334T (84)	L619P (84)
N133T (167)	I335T (84, 141) V (184)	G629S (88, 141)
N138S,H*,T (61, 66, 84, 88, 178)	L336R,P (88)	R632C (167)
A139P (84)	Y337E,C (163)	L634F (84)
S140A,N (84)	W341S,G (59,139)	A636E (92)
L141F (59)	T344A,P (152,175)	L653P (92)
D142A (84)	K345T (92)	F658V (59)

Author Manuscript

Author Manuscript

Author Manuscript

Author Manuscript

K143T (92)	P347L* (152)	L662R (139)
A144V (139)	A350S,T (84, 141)	G685R (135)
R146W (93)	Q352STOP (155)	D695A,G (162,172)
L148A,P (84, 170)	A361D (133)	G699Q (102)
Y155C (92) S (157)	T363A (152)	S700P (84,157)
Y155C (92) S (157)	T363A (152)	S700P (84, 157)
S160L (84)	P365S* (152)	V708P (146)
cc478-479 del (167)	F368L* (152)	V710A (84)
A162T (92)	G372 ins (88)	c139 del (139)
G169A (163)	S374P* (152)	A713P (66)
A172T (66, 84) V (153)	L378P (133)	A714P (84)
M176I,T (153, 167)	A379T (142) V (133)	A716P (141)
T180C (84) K (66)	T380I (153)	Q717P (66)
G186V,H (153)	D381G (141)	V725A (146)
W191R, STOP (102, 172)	S383P (167)	A726T (139)
g572 del (153)	L384R (92)	A727D (159)
WE191-192 del (167)	D387H (167)	W728C (92)
E195K (61)	P388L,S (152)	D735 del (92)
W198stop (84)	T390I (153)	D735A (66, 84), N (92)
K200E (139), STOP (84)	L390 ins (146)	
W204R	I393N (84)	

[#] Asterisk (*), found in INH-resistant and/or INH-sensitive strains.

TABLE 4

Biochemical activity of KatG variants (87, 146, 167)

Activity	Variant		
	Similar to wt	Partial	None
Catalase peroxidase	A110V, A139P, A245V, S315N, S315T, R463L, L587M, L619P, L634F, D735A	L48Q	L141F, T275P, Q295P, G297V, T324P, L587P
INH oxidase	L48Q, A110V, A245V, R463L	A139P, Q127E, N133T, L141F, P232S, Q295P, G297V, T324P, S383P, D387H, D419H, M420T, R489S, L634F, D735A	M176T, S315 (N,R,T), D542H, L619P, R632C